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Abstract 
 
Background: In recent years, there has been an increase in the use of automated 
healthcare databases for drug safety in pregnancy evaluation; their suitability for 
this purpose needs to be evaluated. 
 
Aim: To evaluate the utility of the United Kingdom’s General Practice Research 
Database (GPRD) to act as an alternative to pregnancy registries, using 
anticonvulsants as a case study.  
 
Methods: Pregnancies in women with epilepsy were identified and first trimester 
anticonvulsant exposure was determined. Major congenital malformations in the 
offspring were identified and verified. The risk of major congenital 
malformations following exposure to a range of anticonvulsants was calculated 
and compared to those reported by the UK Epilepsy and Pregnancy Register. The 
ability to identify a known teratogenic association using GPRD data was also 
assessed. An algorithm was created to identify and classify different types of 
pregnancy loss in an automated manner.  
 
Results: The risks of a pregnancy outcome with a major congenital malformation 
following first trimester anticonvulsant exposures, were found to be similar in 
the GPRD to those of the UK Register. The number of exposures to individual 
products in the GPRD was often small and therefore lacked statistical power. It 
was, however, possible to identify a known teratogenic association using data 
from the GPRD. Verification of the algorithm developed to classify pregnancy 
losses demonstrated that, although not perfect, it would be a beneficial tool 
when using the GPRD for drug safety in pregnancy research. 
 
Conclusion: It is unlikely a single data source or study design will be sufficient for 
monitoring all aspects of the safety of medicine use during pregnancy. The GPRD 
has the potential to make a valuable contribution to this field of research and 
could play an important role in complementing the work of other surveillance 
systems.  
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Introductory statement 
 
This thesis reports on the potential of using the General Practice Research 
Database as an alternative to pregnancy exposure registries for monitoring the 
safety of medicine use during pregnancy. This thesis contains published and 
unpublished research. Chapters 6 and 7 have been published as peer reviewed 
original research; Chapter 8 will be submitted for publication. The publications 
are the product of a joint collaboration between the University of Bath and 
GlaxoSmithKline. The study was largely funded by GlaxoSmithKline. 
 
For the work presented in Chapters 6 and 7, I led on the protocol development 
with valuable input from individuals at both GlaxoSmithKline and the University 
of Bath. I was responsible for identifying all anticonvulsant product codes and 
medical codes relating to pregnancy, epilepsy and congenital malformations. The 
data extraction from the GPRD was performed by Sayantani Ray at 
GlaxoSmithKline. All verification of congenital malformations and analyses were 
carried out by me at the University of Bath.  
 
For the work presented in Chapter 8, Corinne de Vries and Julia Snowball at the 
University of Bath identified all pregnancy codes and Julia Snowball wrote the 
program for the termination of pregnancy algorithm. I was involved in reviewing 
all medical codes, manually reviewing patients’ medical records and comparing a 
sample of pregnancy losses identified and classified using the algorithm with 
those from the manual review. Amendments to the algorithm were subsequently 
made based on the manual review comparison carried out by myself and others 
at the University of Bath. I carried out the verification of a sample of algorithm 
endpoints by reviewing additional non-coded information recorded by GPs in the 
patients’ medical records.  
 
The inclusion of manuscripts that were written up for publication within this 
thesis does result in a small amount of repetition in the methods sections. 
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Chapter 1 
 
Introduction 
 14 
Before the 1960s, when it was discovered thalidomide was a major teratogen,(1) 
little consideration had been given to the lack of available information regarding 
the safety of medicines when used by women during pregnancy. The realisation 
that thalidomide, which had been specifically marketed to pregnant women, was 
responsible for causing serious birth defects in several thousand infants exposed 
to the drug in utero,(2) alerted governments to the potential dangers associated 
with medicine use during pregnancy. Following this discovery, the need for 
tighter control and regulation of all aspects of the licensing of new medicinal 
products was recognised and, in particular, the need to evaluate the safety of 
medicine use during pregnancy. 
 
The percentage of pregnancies exposed to medicine use has been reported to be 
anywhere between 27 and 99%(3-6) depending on the country of study, the 
definition of ‘medicine use’ and whether the first trimester alone or the entire 
pregnancy period was considered. This high percentage consists of a 
combination of different forms of exposure. In some circumstances exposure will 
be unavoidable, owing to the potential risks to both mother and foetus of the 
underlying medical condition (e.g. epilepsy) which makes discontinuation of 
treatment inadvisable. There will also be exposures that occur as the result of 
the woman developing a new medical condition during pregnancy that requires 
treatment (e.g. an infection). In addition, many exposures to prescription 
medicines during pregnancy will occur inadvertently and these largely result 
from the fact that between 30-50% of pregnancies are unplanned.(7, 8) Women 
can also be exposed to products that have been on the market for a long time, 
which are often available over-the-counter, without a prescription, where there 
can be a false perception that they are safe, even though their safety when used 
during pregnancy has not been specifically evaluated. Knowledge of a particular 
medicine’s safety in relation to pregnancy, is important to provide women and 
healthcare professionals with sufficient information to enable them to make 
informed decisions about their treatment. In many cases this knowledge can also 
provide some level of reassurance following inadvertent exposures, helping to 
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avoid undue concern and potentially the unnecessary decision to have a 
termination of pregnancy. 
 
There are many theories and methods that are applied in the general field of 
drug safety that cannot be applied to drug safety in pregnancy. Although animal 
studies, in some instances, can alert scientists to areas of potential concern, the 
teratogenic effects observed in animals cannot always be extrapolated to predict 
those in humans.(9, 10) Pregnant women are often excluded from clinical trials and 
the number of inadvertent exposures is too small to provide any reliable 
evidence on potential increases in risk.(11) In addition, it is not possible to assume 
a ‘class effect’ as drugs within the same drug class do not always act in a uniform 
manner. Although data on a drug’s pharmacology and toxicology can be 
available, the substantial gaps in our knowledge of teratogenic mechanisms 
mean that it is often of limited value.(12) The field of drug safety in pregnancy also 
differs owing to the further complication of the foetus as an ‘innocent 
bystander’;(12) a treatment that is required for the benefit of one individual has 
the potential to have an adverse effect on a second individual, who can expect 
only indirect benefits (i.e. a healthy mother). As a result of all these factors, 
evaluating the safety of a medicine when used during pregnancy is virtually 
impossible before it is granted a licence. Therefore much of the focus of the 
assessment of a product’s safety has to be given to monitoring pregnancy 
outcomes in women who use the product during pregnancy, once it is on the 
market.  
 
The last fifty years have seen the introduction of a number of methods to 
evaluate the safety of medicine use during pregnancy with the risk of major 
congenital malformations often being the main outcome of interest. Initially drug 
safety in pregnancy surveillance consisted of the collation of spontaneous 
reports of adverse events sent by healthcare professionals and patients to 
pharmaceutical companies.(13) The late 1970s and early 1980s then saw the 
development of a number of case-control surveillance systems that recruited 
infants with and without congenital malformations, with the aim of evaluating 
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associations between medicine use and pregnancy outcomes.(14) Some of these 
systems are still actively recruiting today(15) and unlike spontaneous reports, the 
nature of the case-control study design means they are particularly suited to 
testing hypotheses that have been generated by other types of surveillance 
systems. At a similar time, the first teratology information services (TIS) were set 
up with the aim of identifying exposed pregnancies and following them up to 
capture pregnancy outcome data.(16) Later, the role of the TIS was broadened to 
also act as a point of contact for women and healthcare professionals who 
needed information and advice regarding in utero drug exposures. In 1979 the 
European Concerted Action on Congenital Anomalies and Twins (EUROCAT) was 
set up. EUROCAT aimed to capture and combine European-wide registrations of 
congenital anomalies to identify evidence of clusters associated with 
environmental exposures.(17) In addition to environmental exposures, when 
registering a congenital anomaly there is also the option of recording 
information on maternal drug exposure. In recent years EUROCAT has begun to 
utilise this information to evaluate the safety of some medicines when used 
during pregnancy.(18)  
 
In 1984 the pharmaceutical company Burroughs Wellcome Co. established the 
first pregnancy exposure registry as a tool to monitor the safety of acyclovir 
when used by pregnant women.(19) Since then, pregnancy exposure registries 
have become one of the most commonly used methods for identifying pregnant 
women and pregnancy outcomes in order to evaluate the safety, largely of new 
medicines, when used during pregnancy.  
 
Despite the development of spontaneous reporting systems, teratology 
information services, case-control surveillance systems and pregnancy exposure 
registries, fifty years after the thalidomide disaster there are still a large number 
of medicines, both new and old, where little, if anything, is known about their 
safety when used by pregnant women. The introduction of risk management and 
risk minimisation plans and the United States Food and Drug Administration 
(FDA) 2007 Amendment Act(20) all put increasing emphasis on the requirement 
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for market authorisation holders to be proactive in evaluating the safety of their 
products, when used during pregnancy.(21) Given the current increase in the 
electronic capture of healthcare data for administrative, clinical audit and 
research purposes and given the limitations of some existing data sources and 
methods, increasingly, electronic healthcare and claims data are being used for 
drug safety studies – including drug safety in pregnancy. This has been done both 
for signal strengthening or hypothesis testing and for hypothesis generating 
studies. As these increase in popularity and given the methodological challenges 
specific to drug safety in pregnancy research, there is a need to evaluate these 
data sources individually to determine their potential as new and 
complementary data sources in this area. 
 
This PhD aims to evaluate the potential of the United Kingdom’s General Practice 
Research Database (GPRD) to be used as an alternative or complement to 
pregnancy registries in monitoring the safety of medicines when used by 
pregnant women. The next chapter will discuss the strengths and limitations of 
pregnancy exposure registries, before introducing the reader to additional data 
sources that are currently available and used in this area of research. The work 
presented in this chapter builds on that published in 2008,(22) before I registered 
to study for a PhD. This is followed by an outline of the specific aims and 
objectives of the PhD (Chapter 3). Chapter 4 then provides information on the 
GPRD, discusses features of the database that are specific to monitoring the 
safety of medicine use during pregnancy and summarises key research in this 
field using the GPRD to date. The focus of the thesis is exposure to 
anticonvulsants; the fifth chapter explains the rationale behind this choice. The 
methods and results of a study that verified congenital malformations identified 
in the GPRD and evaluated the sensitivity and added value of photocopied 
medical records and free text are discussed in Chapter 6. Chapter 7 presents the 
findings of a study that compared the rates of major congenital malformations in 
the GPRD with those reported by the UK Epilepsy and Pregnancy Register. This 
chapter also reports on the potential of the GPRD, when I attempted to identify a 
known teratogenic association. Chapter 8 outlines the importance of including 
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pregnancy losses when assessing the safety of medicines used during pregnancy 
and reports on work carried out to identify and categorise pregnancy losses in an 
automated manner in the GPRD. In the final chapter I outline how I have met 
each of the objectives set out in Chapter 3 and discuss the findings and their 
implications. Then, based on all the evidence presented in this thesis, I will draw 
final conclusions on the potential of the GPRD in the field of drug safety in 
pregnancy research and the areas where I believe it has been demonstrated it 
can make a valuable contribution.  
 
 
 
References 
 
1. McBride W. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358. 
2. Lenz W. A short history of thalidomide embryopathy. Teratology. 
1988;38(3):203-15. 
3. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during pregnancy in 
developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 
2011;20(9):895-902. 
4. Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early pregnancy-
prevalence and determinants of use in a prospective cohort of women. 
Pharmacoepidemiol Drug Saf. 2010;19(4):408-17. 
5. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs 
during pregnancy in France. Lancet. 2000;356(9243):1735-6. 
6. Garriguet D. Medication use among pregnant women. Health Reports. 
2006;17(2):9-18. 
7. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect. 
1998;30(1):24-9. 
8. Lakha F, Glasier A. Unintended pregnancy and use of emergency contraception 
among a large cohort of women attending for antenatal care or abortion in 
Scotland. Lancet. 2006;368(9549):1782-7. 
9. Hoar RM. Developmental toxicity: extrapolation across species. J Am Coll 
Toxicol. 1999;14(1):11-20. 
10. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 
1998;338(16):1128-37. 
11. Shields KE, Wiholm B, Hostelley LS, et al. Monitoring outcomes of pregnancy 
following drug exposure: a company-based pregnancy registry program. Drug 
Saf. 2004;27(6):353-67. 
12. Mitchell A. Studies of drug-induced birth defects. In: Strom BL, editor. 
Pharmacoepidemiology: John Wiley and Sons Ltd; 2005. p. 501-14. 
13. Cunnington M, Messenheimer J. Pregnancy Registries: strengths, weaknesses, 
and bias interpretation of pregnancy registry data. Int Rev Neurobiol. 
2008;83:283-304. 
 19 
14. Werler MM, Louik C, Mitchell AA. Case–control studies for identifying novel 
teratogens. Am J Med Genet C Semin Med Genet. 2011;157(3):201-8. 
15. Louik C, Schatz M, Hernández-Díaz S, et al. Asthma in pregnancy and its 
pharmacologic treatment. Ann Allergy Asthma Immunol. 2010;105(2):110-7. 
16. Leen-Mitchell M, Martinez L, Gallegos S, et al. Mini-review: History of organized 
teratology information services in North America. Teratology. 2000;61(4):314-7. 
17. Dolk H. EUROCAT: 25 years of European surveillance of congenital anomalies. 
Arch Dis Child Fetal Neonatal Ed. 2005;90:F355-F8. 
18. Dolk H, Jentink J, Loane M, et al. Does lamotrigine use in pregnancy increase 
orofacial cleft risk relative to other malformations? Neurology. 2008;71:714-22. 
19. Andrews EB, Yankaskas BC, Cordero JE, et al. Acyclovir in pregnancy registry: six 
years' experience. The Acyclovir in Pregnancy Registry Advisory Committee. 
Obstet Gynecol. 1992;79(1):7-13. 
20. HR 3580 FDA Amendments Act, 2007, Sec 905; D.i.II.Bb. 
21. Wyszynski DF. Pregnancy exposure registries: Academic opportunities and 
industry responsibility. Birth Defects Res A Clin Mol Teratol. 2009;85:93-101. 
22. Charlton RA, Cunnington MC, de Vries CS, et al. Data resources for investigating 
drug exposure during pregnancy and associated outcomes: the General Practice 
Research Database (GPRD) as an alternative to pregnancy registries. Drug Saf. 
2008;31(1):39-51. 
 
 
 
 
 
  
 
 
 
 20 
 
Chapter 2 
 
Alternative data sources to 
pregnancy exposure registries 
 
 
 21 
2.1 An overview of pregnancy exposure registries 
Pregnancy exposure registries are essentially prospective observational studies 
that follow women up from the time of enrolment in the registry until a short 
period after pregnancy outcome. They are created with the aim of detecting 
major teratogenicity, that is, where a large proportion (e.g. 30-40%) of those 
pregnancies exposed to a particular drug are adversely affected.(1) Pregnancy 
exposure registries can be set up either by pharmaceutical companies, academic 
groups or research groups, they can be international or country specific and they 
can focus on a single drug, a drug class or a disease. The European Medicines 
Agency and the FDA recommend pharmaceutical companies consider developing 
a pregnancy exposure registry for products that may be used during pregnancy 
to treat new or chronic conditions and for products frequently used by women of 
childbearing age where the likelihood of inadvertent exposure during pregnancy 
is high.(2, 3)  
 
Pregnancy exposure registry methods 
The precise methodology used can vary slightly between registries but in general, 
women can enrol either directly themselves or via one of their healthcare 
providers (GP, midwife, epilepsy nurse etc.). Enrolment should ideally be before 
any prenatal screening has taken place and before the pregnancy outcome is 
known in order to avoid selection bias towards more severe outcomes. At the 
time of enrolment, informed consent is obtained and information is collected on 
some or all of the following: general demographics, use and timing of 
prescription and over-the-counter medicines, disease status (e.g. number / type 
of epilepsy seizures), potential confounding factors including smoking status, 
alcohol consumption and folic acid exposure. Given our knowledge of the 
different stages of foetal development, pregnancy registries have tended to 
focus their analysis on pregnancies where drug exposure occurred during the 
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first trimester of pregnancy as this is the time period of greatest susceptibility in 
terms of the risk of major congenital malformationsa (Figure 2.1).   
 
 
Figure 2.1 Human embryonic development showing sensitive periods (From Moore, 
1988(4) with permission)  
 
Follow up information on the pregnancy outcome and the presence or absence 
of a congenital malformation is collected, shortly after the expected date of 
delivery, by a GP or patient questionnaire or telephone call. Live births, 
stillbirths, induced terminations and spontaneous abortions are captured by 
registries although the number of spontaneous pregnancy losses captured may 
be relatively low depending on the week’s gestation at which women enrol. The 
primary endpoint of a pregnancy registry is an estimate of the overall risk of all 
major congenital malformations(5) with the aim of providing data based on 
exposures in humans that is clinically relevant and can be used to inform 
healthcare professionals and patients.(6) In addition to collecting information on 
congenital malformations, some registries have chosen to extend the length of 
infant follow-up in order to evaluate any evidence of an association between 
maternal drug exposure and developmental delay in the offspring.(5) 
                                                             
a
 Major congenital malformations will be discussed in more detail in Chapters 6 and 7 but they     
are broadly defined as abnormalities present at birth that are of surgical, medical or cosmetic 
importance 
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To reduce the likelihood of selection bias, analysis of data collected by pregnancy 
exposure registries tends to focus on those pregnancies that were prospectively 
enrolled before any prenatal screening or knowledge of the pregnancy outcome 
has occurred. Pregnancies reported to registries retrospectively, following the 
diagnosis of a major congenital malformation, are still reviewed and analysed 
because they may help to identify multiple cases of the same defect type, which 
would require further investigation.(6)  
 
In addition to the main aim of identifying major teratogenicity, pregnancy 
exposure registries can also act as hypothesis-generating studies by detecting 
adverse pregnancy outcomes that may warrant further investigation. To do this 
many pregnancy registries have adopted the ‘rule of 3’ where review is thought 
warranted if the registry observes 3 or more reports to be of a particular defect 
following the same exposure. The ‘rule of 3’ is based on the rationale that in a 
registry with fewer than 600 exposures, the likelihood of observing 3 of the same 
specific birth defect when it normally occurs with a rate of less than 1/700 is 
unlikely to be by chance alone.(7) 
 
Limitations of pregnancy exposure registries 
Although pregnancy registries have several strengths over other surveillance 
methods it is widely recognised that they also have a number of limitations. 
 
Enrolment 
Low levels of enrolment are commonly found to hinder pregnancy exposure 
registries. The European Committee for Medical Products for Human Use 
considers 1000 exposures to be representative of widespread market 
exposure,(8) yet the pharmaceutical company GlaxoSmithKline has sponsored five 
international registries, none of which managed to enrol 1000 pregnancies with 
informative outcomes during their first ten years of data collection.(9) Attempts 
to raise awareness and encourage enrolment are often hampered by the lack of 
knowledge regarding the safety of the product being monitored, making it 
difficult to decide on how to communicate the message and the need to ensure 
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any promotional material does not appear to encourage use of the product or 
give a false impression of safety.(6, 10)   
 
The voluntary nature of enrolment can result in selection bias if women opting to 
enrol differ from those who do not, in terms of factors associated with the 
underlying risk of the outcome being studied.(11) For example, women choosing 
to enrol into a registry may be more health conscious and more likely to follow 
advice in relation to the potential benefits of pre-conceptional folic acid, smoking 
cessation and reducing alcohol intake during pregnancy than those who do not. 
In addition to selection bias resulting from enrolment by the women themselves, 
registries may also suffer from referral bias with healthcare professionals being 
more or less likely to enrol women with a particular disease severity or those 
exposed to a particular type of treatment. To my knowledge thus far no 
comparisons have been published comparing the population characteristics and 
disease severity for individuals enrolled in a pregnancy registry with those from a 
representative sample of individuals who would be eligible to enrol.   
 
Loss to follow-up 
Pregnancy exposure registries often suffer from loss to follow-up. This has been 
reported to be as low as 8.1% in the UK Epilepsy and Pregnancy Register(12) and 
as high as 35.8% in the Buproprion Pregnancy Registry.(13) In 2004, in an attempt 
to reduce loss to follow-up, three pregnancy registries trialled the introduction of 
a stipend for healthcare professionals who reported follow-up pregnancy 
outcome data to the registry. Analysis of loss to follow-up rates before and after 
this introduction found the incentive of a stipend, to reimburse healthcare 
professionals for the time taken to report follow-up pregnancy outcome data, 
did not significantly reduce the proportion of pregnancies lost to follow-up.(14)  
 
Statistical power 
A combination of low enrolment, loss to follow-up and a low frequency of the 
exposure and outcome of interest can limit the statistical power and validity of 
pregnancy exposure registries. At best, pregnancy registries are often only 
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powered to detect major teratogens and evaluate the risk of all major congenital 
malformations combined. There may, however, be instances where a registry 
generates a signal relating to an increased risk of a particular defect type.(15) In 
these instances, although data from other pregnancy registries monitoring the 
same exposure can be analysed in an attempt to confirm of refute the possible 
association, it is likely that they too will lack statistical power and therefore 
additional data sources will be required to investigate further.  
 
Information on potential confounders 
When sample sizes are small, the inclusion of too many confounding variables 
can make any statistical models of risk assessment unstable but as more 
individuals are enrolled the number of confounding variables considered can 
potentially be increased.(16) Pregnancy exposure registries, however, require 
primary data collection, which can be both costly and time consuming. This can 
often mean that less information on potential confounding variables is requested 
so as not to dissuade pregnant women and healthcare professionals from 
choosing to enrol.(17) For the identification of a high-risk teratogen a lack of this 
information, although restrictive, is unlikely to dramatically alter the risk 
estimates.(1)   
 
Comparator group 
The selection of a suitable comparator group when evaluating data from 
pregnancy exposure registries is challenging, especially when there is a possibility 
that the medical condition that the treatment is for may itself be associated with 
the outcome of interest (e.g. diabetes, epilepsy).(11) There are many possible 
comparator groups that can be used and the most appropriate will depend on 
the question being asked and the exposure and outcome of interest. Some 
analyses carried out by registries involve making comparisons with population-
based birth defect surveillance systems such as the Metropolitan Atlanta 
Congenital Defects Program (MACDP),(7) some make comparisons with other 
monotherapy exposures that have been collected via the registry, some 
registries enrol women who have the disease but were not treated during 
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pregnancy,(12) some enrol their own unexposed comparator group such as family 
or friends of the exposed woman(18) and some make multiple comparisons using 
a combination of the comparator groups mentioned. It could be argued 
however, that given the aim, to identify major teratogenicity, no formal 
comparator group is needed and instead comparison with background 
prevalence should be sufficient.(1, 19) 
 
2.2 Literature search to identify alternative data sources to pregnancy exposure 
registries  
Pregnancy exposure registries have been successful in both providing 
reassurance that certain products are not major teratogens(20) and in generating 
signals of potential teratogenicity that require further investigation.(15)  Their 
limitations, however, along with the acceptance that a single data source is 
unlikely to be sufficient to provide all the answers, have led researchers to look 
for alternative and complementary sources of data for evaluating prenatal drug 
exposures.  
 
One alternative type of data source that is becoming the focus of much research 
is that of electronic healthcare databases. Electronic databases are increasingly 
being used to manage medical insurance claims and patient medical records and 
this has resulted in an ever-growing volume of healthcare data being available 
for pharmacoepidemiology research. The initial signal that suggested a possible 
association between first trimester exposure to paroxetine (a selective serotonin 
reuptake inhibitor (SSRI)) and an increased risk of major congenital 
malformations and cardiovascular defects resulted from a study based on 
electronically recorded healthcare claims data from the United States.(21) Given 
that there was no pregnancy exposure registry set up for paroxetine this 
potential association could have otherwise gone undetected. Following the initial 
study a number of other studies were conducted using a range of different data 
sources and epidemiological study designs in order to try to confirm or refute the 
association.(22-26) The findings of these studies ultimately resulted in changes 
being made to the product label.(27) 
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Additional sources of information on drug exposures during pregnancy and 
pregnancy outcomes have the ability to complement pregnancy exposure 
registries in a number of ways. The remainder of this chapter reports on a 
literature review carried out to identify additional data sources that are currently 
being used to monitor the safety of medicine use during pregnancy. This review 
builds on the review that was published in January 2008 (Appendix I).(9) 
 
Methods 
A review of the literature was conducted to identify papers (excluding 
conference abstracts) reporting on the safety of medicine use during pregnancy 
that had used a data source which had systematic data collection. In PubMed 
papers were identified based on the following search: ((‘Pregnancy’[Mesh] OR 
‘Congenital Abnormalities’[Mesh] OR ‘Teratogens’[Mesh]) AND (‘Product 
Surveillance, Postmarketing’[Mesh])), whilst in Embase papers were identified 
based on ((‘Pregnancy’ OR ‘Pregnancy outcome’ OR Pregnancy termination’ OR 
‘Congenital disorder’ OR ‘Congenital malformation’ OR ‘Birth defects’ OR 
‘Teratogenic agent’  OR ‘Teratogenicity’) AND (‘Postmarketing surveillance’ OR 
‘Drug surveillance program)) and were restricted to papers reporting on studies 
in Humans. All papers were restricted to those published in English between 1 
January 2000 and 30 November 2011. In addition to searching the literature, 
individuals who are specialists in the field of drug safety in pregnancy were 
consulted to ensure any additional data sources were captured. 
 
Results 
The literature searches identified 236 articles through PubMed and a further 381 
articles via Embase. Of these 505 were excluded following review of the title and 
abstract and a further 30 were excluded following review of the full text (Figure 
2.2).  
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Figure 2.2 Identification of articles in the literature 
 
Table 2.1 summarises the rationale for excluding the papers identified and 
excluded at this stage. A total of 82 articles were included. Overall the studies 
reported on used data from 19 different data sources. A further 6 data sources 
were identified and included as a result of my knowledge of the sources available 
and by contacting specialists in the field. Table 2.2 provides an overview of each 
of the 25 data sources identified. Where the papers identified via the literature 
search did not have sufficient information to complete all the fields in the table, 
additional papers reporting on those sources where identified. Where 
information was still missing, the authors of the papers were contacted.  
 
 
 
 
 
 
 
Articles identified via PubMed search 
 
N = 236 
Distinct articles 
N = 617 
Articles identified via Embase search 
 
N =390 
Eligible for full article review 
N = 112 
Eligible articles identified 
N = 82 
Exclude based on full 
article review 
N =30 
Exclude based on title and 
abstract review 
N = 505 
Data sources identified 
N = 19 
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Table 2.1 Summary of the rationale for those articles excluded 
Reason for exclusion Number of 
articles 
excluded 
Pregnancy exposure registries 23 
Teratology information centres 17 
Field studies with one-off manual data collection 16 
Meta-analyses 7 
Spontaneous/case reports 11 
Environmental or occupational exposures 19 
Alcohol or illicit drug use exposures 6 
Overview of teratogenicity in general or pregnancy exposure 
registries 
47 
Comments or letters to the editor  97 
Review papers 154b 
Other (e.g. product surveillance in general - not specifically 
pregnancy, reviews of medical conditions during pregnancy) 
138b 
 
                                                             
b
 These categories are large but they mainly come from the Embase search where the search   
  strategy is not as refined as in PubMed and this results in a large number of unrelated  
  publications being identified 
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Table 2.2 Summary of the data sources identified to evaluate the safety of medicine use during pregnancy  
Key: Dark text represents those variables captured by the data source and light text represents those variables that are not available. 
Name of data source Time period of 
data collection 
Population covered Source of exposure 
information 
Types of pregnancy 
outcome captured 
Source of outcome 
information 
Additional risk information 
(all capture maternal age) 
 
Population-based record linkage surveillance systems 
 
Swedish Medical Birth 
Register
(22, 28)
 
 
 
Medical birth 
register since 
1973, including 
drug use since July 
1994 
 
Prescribed drug 
register since 2005 
Country 
Sweden 
 
Population-based – Yes 
~98% of all deliveries  
 
Sample size 
~110,000 births per year 
 
Maternal self 
reporting at first 
antenatal interview 
and copies of 
antenatal care 
records are reviewed 
 
Prescribed drug 
register of filled 
prescriptions since 
2005 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Identified from the 
Register of Birth 
Defects and the Patient 
Register – data 
recorded by a 
paediatrician 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid 
    - if reported 
 Over-the-counter medicines 
    - if reported 
 Reproductive history 
 
Norwegian Medical 
Birth Register
(29, 30)
 
 
Medical birth 
registry of Norway 
since 1967, 
including drug use 
since 1998 
 
Norwegian 
Prescription 
database since 
2004 
 
Country 
Norway 
 
Population-based – Yes 
Compulsory reporting of 
all births and late 
abortions from 12 weeks 
gestation  
 
Sample size 
~60,000 births per year 
Recorded during 
antenatal visits to 
GP, midwife and 
obstetrician. 
 
Potential to use 
prescribed drug 
register of filled 
prescriptions since 
2004 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 - from 12 weeks    
gestation 
 
Recorded by physicians 
and midwives 
 
Opportunity for 
medical record review - 
Yes 
 Smoking status – since 1998 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid  
    - Since 1998 
 Over-the-counter medicines 
    - if the GP is aware 
 Reproductive history 
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Finnish linked national 
health registers
(31, 32) 
 
Medical birth 
register since 1987 
 
Register on 
induced abortions 
since 1977 
 
Register of 
reimbursement 
drugs since 1994 
Country 
Finland 
 
Population-based – Yes 
Compulsory reporting of 
all deliveries and elective 
terminations  
 
Sample size 
~58,000 deliveries and 
~ 10,500 elective 
terminations per year  
 
Information on 
reimbursed 
purchases of 
prescription 
medicines from the 
Register of 
Reimbursement 
Drugs 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Will have spontaneous 
losses treated in  
hospital and primary 
care from 2011 
Identified from the 
register of congenital 
malformations – data 
recorded by hospital 
personnel. 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses - chronic 
 Co-prescribing 
 Folic acid – high dose only 
 Over-the-counter medicines 
 Reproductive history 
 
Danish National 
Patient Registry
(33-35)
 
 
 
 
Danish National 
Patient Registry 
since 1996 
 
Prescription data 
from 1995 but 
only available 
since 2003 
 
Country 
Denmark 
 
Population-based – Yes 
Compulsory reporting of 
all births 
 
Sample size 
~50,000 deliveries per 
year  
 
Filled prescription 
data from the 
Registry of Medicinal 
Product Statistics 
since 2003 
 
Previously would 
have been self 
reported via 
maternal interview 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
Routinely recorded 
inpatient and 
outpatient data 
recorded by 
paediatrician 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses  
- hospital diagnoses only 
 Co-prescribing 
 Folic acid – high dose only 
 Over-the-counter medicines 
 Reproductive history 
 
The North Jutland 
Pharmaco-
Epidemiological 
Prescription Database 
with linked 
registries
(36)
 
 
 
Prescription 
database since 
1991  
 
Danish National 
Patient Registry 
since 1996 
 
 
Country 
Denmark 
 
Population-based – Yes 
County of North Jutland - 
compulsory reporting of 
all births 
 
Sample size 
~6,000 deliveries a year 
Dispensed 
prescription data 
used to secure 
reimbursement from 
the Health Service to 
the pharmacies 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
County hospital 
Discharge Register – 
discharge diagnoses 
recorded by 
paediatrician 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses  
- hospital diagnoses only 
 Co-prescribing 
 Folic acid – high dose only 
 Over-the-counter medicines 
 Reproductive history 
 
 32 
Saskatchewan 
population 
registries
(37, 38)
 
 
 
Hospital data from 
1970 
 
Prescription data 
from 1975 
Country 
Canada 
 
Population-based – Yes 
Covers >90% of the 
Canadian province 
 
Sample size 
~11,400 deliveries per 
year  
 
 
Dispensed 
prescriptions on the 
Outpatient 
Prescription Drug 
Database 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
Identified from the 
Hospital Services 
Database – data 
recorded electronically 
by physician 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses  
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
Taiwan National 
Health Insurance 
Research Dataset 
linked to the Birth 
Certificate Registry
(39)
 
Since 1996  Country 
Taiwan 
 
Population-based – Yes 
~98% of the Taiwan 
population 
 
Sample size 
~200,000 births per year 
Dispensed 
prescription data 
recorded in the 
National Health 
Insurance Research 
Dataset 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Identified from medical 
claims recorded in the 
National Health 
Insurance Research 
Dataset 
 
Opportunity for 
medical record review - 
No 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status 
   - maternal education only 
 Maternal diagnoses 
 Co-prescribing 
 Folic acid  
 Over-the-counter medicines 
 Reproductive history 
 
 
Western Australia 
population-based 
Data Linkage 
System
(40, 41)
 
 
 
Since 2002 
 
Birth defect 
registry since 1980 
Country 
Australia 
 
Population-based – Yes 
All pregnancies in 
Western Australia  
 
Sample size 
~ 40,000 pregnancies a 
year 
 
Dispensed 
prescriptions. Covers 
those issued in 
community and 
private hospitals and 
from 2004 public 
hospitals that are 
subsidised ~80% of 
all prescriptions 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Looking into linking 
elective terminations 
with the birth defect 
registry 
Notifications received 
from paediatricians, 
obstetricians, 
cytogenetics, 
ultrasound, genetic 
counselling 
departments to the 
Birth Defects Registry 
of western Australia. 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status 
 Maternal diagnoses 
 Co-prescribing 
 Folic acid  
 Over-the-counter medicines 
 Reproductive history 
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Region Emilia-
Romagna (RER) 
Database
(42)
  
Since 2000 Country 
Italy 
 
Population-based – Yes 
~99% of pregnancies in 
Region Emilia-Romagna 
 
Sample size 
~ 33,000 pregnancies a 
year 
 
Reimbursed 
prescription data 
 
(~70% of medicines 
can be reimbursed) 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Hospital assistance at 
birth records, hospital 
discharge records and 
links to Congenital 
anomaly register 
 
Opportunity for 
medical record review -
No 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status 
 Maternal diagnoses 
 Co-prescribing 
 Folic acid  
 Over-the-counter medicines 
 Reproductive history 
 
 
Healthcare databases 
Medical record databases 
 
General Practice 
Research Database
(43, 
44)
 
Since 1987 Country 
United Kingdom 
 
Population-based – Yes 
~8% sample of the UK 
population 
 
Sample size 
~80,000 pregnancies per 
year 
 
Prescriptions issued 
by GPs and recorded 
in medical records  
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Diagnoses recorded in 
medical records by GPs 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid – high dose only 
 Over-the-counter medicines 
 Reproductive history 
 
The Health 
Improvement 
Network (THIN)
(45, 46)
 
 
Since 2003 Country 
United Kingdom 
 
Population based – Yes 
~6% sample of the UK 
population 
 
Sample size 
~60,000 pregnancies per 
year 
Prescriptions issued 
by GPs and recorded 
in medical records 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Diagnoses recorded in 
medical records by GPs 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid – high dose only 
 Over-the-counter medicines 
 Reproductive history 
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Administrative claims databases 
 
Tennessee 
Medicaid
(47, 48)
 
 
 
Since 1985 Country 
United States 
 
Population-based – No 
- generally low income 
adults 
 
Sample size 
~36,000 deliveries per 
year  
 
Pharmacy claims 
data for dispensed 
prescriptions 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
Identified from 
Medicaid inpatient, 
emergency department 
physician visit, hospital, 
discharge diagnoses 
records  
 
Also link to birth and 
foetal death certificates 
 
Opportunity for 
medical record review - 
Yes 
  
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses - chronic 
 Co-prescribing 
 Folic acid  
 Over-the-counter medicines 
 Reproductive history 
    
 
Kaiser Permanente
(49, 
50)
 
 
Since ~1995 Country 
United States 
 
Population-based – No 
Under-represents those at 
the extremes of 
household income 
 
Sample size 
~30,000 deliveries per 
year  
 
Pharmacy claims 
data for dispensed 
prescriptions 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
Medical claims records 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
    - maternal education only 
 Maternal diagnoses  
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
United Healthcare
(21, 
51, 52) 
 
 
 
 
Since 1990 Country 
United States 
 
Population-based – No 
~2% of US population. 
90% are employer groups, 
Electronically 
recorded dispensed 
prescription data 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
Medical claims records 
from inpatient, 
hospital, outpatient, 
emergency 
department, surgery 
centre and physician’s 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses  
 Co-prescribing 
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some individuals from 
Medicaid population 
 
Sample size 
~32,000 deliveries per 
year.  ~ 75% of infants 
remain in the health plan 
 
office 
 
Opportunity for 
medical record review - 
Yes 
 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
    
 
Régie de l’assurance 
maladie du Québec 
(RAMQ)
(53, 54)
 
 
 
Since 1980 – 
recipients of social 
welfare 
 
Since 1997 – 
workers and their 
families not 
covered under 
private drug 
insurance 
Country 
Canada 
 
Population-based – No 
Drug information for only 
recipients of social 
welfare and those who do 
not have private 
healthcare 
 
Sample size 
~20,000 pregnancies per 
year 
 
Dispensed 
prescription data 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
Diagnoses recorded in 
the administrative 
databases of RAMQ and 
MED-ECHO 
 
Opportunity for 
medical record review - 
No 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses  
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
Clalit Data 
Warehouse
(55, 56)
 
 
 
 
Since 1998 Country 
Israel 
 
Population based - No 
Members of the Southern 
district of Clalit Health 
Services - ~70% of women 
15-49 years 
 
Sample size 
~9,500 births per year  
 
 
Dispensed 
prescription data 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Medical diagnoses 
during hospitalisation 
drawn directly from 
hospital records 
 
Opportunity for 
medical record review -
Yes 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid - some 
 Over-the-counter medicines 
 Reproductive history 
 
 36 
 
Purpose built surveillance systems 
 
Slone Epidemiology 
Unit Birth Defects 
Study
(23, 57)
 
Since 1976 Country 
United States and 
previously Canada 
 
Population based - Yes 
 
Sample size 
To date >40,000 women 
have been interviewed 
 
Self-reporting via 
maternal telephone 
questionnaire  
(face to face 
interview up until 
1998) 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Recorded by a 
paediatrician 
 
Opportunity for 
medical record review -
Yes, with mothers 
permission 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
Opportunity to add additional 
interview questions relevant to 
a particular study. 
 
National Birth Defects 
Prevention Study
(58, 59)
 
Since 1997 Country 
United States  
 
Population based - Yes 
 
Sample size 
~10% of annual US birth 
cohort 
 
Self reporting of 
exposure by 
maternal assisted 
telephone interview 
between 6 weeks 
and 2 years after the 
expected date of 
delivery 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
The capture of 
stillbirths and elective 
terminations varies by 
state 
 
Controls are live births 
only 
Medical record 
extraction 
 
Collect data on a 
sample of specific birth 
defect types but not all 
 
Opportunity for 
medical record review - 
Yes 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
Opportunity to add additional 
interview questions relevant to 
a particular study 
 
The Latin-American 
Collaborative Study of 
Congenital 
Since 1967 Country 
9 countries in South 
America  
Self reported by the 
mother and collected 
by a trained 
 Live births  
 Stillbirths  
 Spontaneous losses 
Identified from 
registered 
malformations 
 Smoking status 
 Alcohol consumption 
 Body mass index 
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Malformations 
(ECLAMC)
(60, 61)
 
 
 
 
 
Population based - Yes 
 
Sample size 
~150 - 200,000 births per 
year 
paediatrician during 
the puerperium 
 Elective terminations 
 
diagnosed at birth 
 
Opportunity for 
medical record review - 
No 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
Collects data on 50 possible 
risk factors 
 
Spanish Collaborative 
Study of Congenital 
Malformations 
(ECEMC)
(62, 63)
 
Since 1976 Country 
Spain 
 
Population based - Yes 
 
Sample size 
~87,000 births per year 
~1,100-1,300 case-control 
pairs per year 
 
Maternal interviews 
with paediatricians 
within the first 3 days 
following delivery. 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Diagnosed by 
paediatricians within 
the first 3 days of life. 
 
Opportunity for 
medical record review - 
No 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
>300 data points of 
information collected. 
 
Hungarian Case-
control of Congenital 
Abnormalities 
Study
(64)
 
 
1980-1996 
 
Appears to be no 
longer recruiting - 
Emailed Professor 
Czeizel but did not 
get a response 
Country 
Hungary 
 
Population based - Yes 
 
Sample size 
In 1996  ~22,843 cases 
and 38,151 controls 
 
Review of antenatal 
log book and medical 
records recorded by 
obstetrician, 
additional data 
requested by 
maternal 
questionnaire 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective termination 
- following a prenatal 
malformation diagnosis  
Cases reported by a 
physician or 
paediatrician during 
first 3 months after 
birth or termination.  
 
Opportunity for 
medical record review - 
Yes, discharge 
summaries 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
    - employment status only 
 Maternal diagnoses 
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
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European Concerted 
Action on Congenital 
Anomalies and Twins 
(EUROCAT)
(65-67)
 
Since 1979 Country 
20 European countries 
 
Population based - Yes 
 
Sample size 
~1.7 million births per 
year 
 
Varies by register – 
hospital records, GP 
records, pharmacy 
records, maternal 
interview 
 
Not all registers 
capture drug 
exposure data 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
Largely reported by a 
physician to a local or 
national congenital 
anomaly register 
 
Opportunity for 
medical record review -
varies by registry 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Co-morbidities 
 Co-prescribing 
 Folic acid 
 Over-the-counter medicines 
 Reproductive history 
 
All vary by register 
 
New data sources undergoing evaluation 
 
Secure Anonymised 
Information Linkage 
Databank (SAIL)
(68)
 
 
 
General practice 
data since 1992 
 
Hospital 
admissions from 
2004 
Country 
Wales 
 
Population based – Yes 
 
Sample size 
~44,000 pregnancies per 
year 
 
Prescriptions issued 
by a GP 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Diagnoses recorded by 
a GP or paediatrician 
 
Opportunity for 
medical record review - 
Yes 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid – high dose only 
 Over-the-counter medicines 
 Reproductive history 
 
German Pharmaco-
epidemiological 
Research Database
(69)
 
 
Assessment of a 
mother-baby link 
in 2010 
Country 
Germany 
 
Population based – No 
German statutory health 
insurances 
 
Sample size 
~83,000 live births per 
year  
Dispensation data of 
reimbursed drugs 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Work is ongoing into 
the capture of 
pregnancy losses 
Under investigation but 
have access to hospital 
data and ambulatory 
physician visits 
 
Opportunity for 
medical record review - 
No 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid  
 Over-the-counter medicines 
 Reproductive history 
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Evaluation chez la 
Femme des 
Medicaments et de 
leurs RISque 
(EFEMERIS 
Database)
(70)
 
 
 
Since 2004 Country 
France 
 
Population based - No 
Pregnant women in the 
Haute-Garonne 
department registered 
under general state 
coverage (~80% of the 
population  
 
Sample size 
~13,500 pregnancies per 
year 
 
Dispensed 
prescription data 
recorded to be sent 
to the French Health 
Insurance System 
Caisse Primaire 
d’Assurance Maladie 
(CPAM) 
 Live births  
 Stillbirths  
 Spontaneous losses 
 Elective terminations 
 
Recorded by physician 
during compulsory 
medical examinations 
at 8 days, 9 months and 
3 years 
 
Prenatal diagnoses  
resulting in a 
termination are 
recorded by the 
antenatal diagnostic 
centre 
 
Opportunity for 
medical record review - 
No 
 
 Smoking status 
 Alcohol consumption 
 Body mass index 
 Socioeconomic status  
 Maternal diagnoses 
 Co-prescribing 
 Folic acid  
 Over-the-counter medicines 
 Reproductive history 
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2.3 Discussion of alternative data sources 
The review of the literature identified a large number of data sources being used 
for drug safety in pregnancy research. Based on the population captured and the 
type of data collected they can be grouped into three broad categories: 
population-based surveillance registers that rely on linked data sets, healthcare 
databases and purpose-built data sources such as case-control surveillance 
systems. Below, the key strengths and limitations of each type of data source are 
summarised. 
 
Population-based surveillance registers  
A key strength of population-based surveillance registers, such as those of the 
Nordic countries, is the mandatory reporting of all live- and stillbirths within a 
country or region. This results in the capture of exposure and outcome data from 
a representative sample of women and reduces concerns about the 
generalisability of study findings. One limitation, however, is that not all of these 
registers capture spontaneous pregnancy losses and induced terminations of 
pregnancy.   
 
In the past, almost all data collected on first trimester drug exposure in these 
registers would have been based on maternal self-reporting during antenatal 
visits. Today, however, many have access to linked prescription data and the 
independent recording by the prescriber has the advantage of removing the 
possibility of recall bias. Capturing prescription data only does, however, mean 
over-the-counter exposures are not covered and there is a lack of information on 
whether the woman actually took the medicine and the precise timing of 
exposure. Studies using population based surveillance registers often identify 
congenital malformations from birth defect registers. As malformations are 
reported to these registers by physicians, midwives or paediatricians, the 
recording and reliability of the data is thought to be high.   
 
Population-based surveillance registers have similar restrictions to pregnancy 
registries in terms of the volume of information that can be feasibly collected on 
covariates of interest, owing to the time available during an antenatal care 
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interview with a midwife. Whilst they all tend to collect data on maternal chronic 
diseases and co-prescribing, data on lifestyle factors such as alcohol intake, 
smoking status and body-mass-index is not always available. 
 
Healthcare databases 
Two main types of healthcare database were identified from the review of the 
literature; those that contain patient medical records and those that are based 
on administrative claims for reimbursement of medical treatment and 
prescriptions. Medical record databases such as the GPRD and The Health 
Improvement Network (THIN) capture data on a representative sample of the UK 
population in terms of age, sex and morbidity.(71)  The representative nature of 
the population captured by claims databases, however, varies by the type of 
insurance policy. The population of Kaiser Permanente, for example, has been 
found to be reasonably representative of the geographical areas that it covers, 
although the extremes of household income are thought to be under-
represented. Tennessee Medicaid, however, is a US government-funded scheme 
and generally captures more mothers from populations with lower socio-
economic status.(72)  
 
Electronic medical record data has the advantage of exposure information being 
recorded prospectively by the prescriber before the pregnancy outcome is 
known.(71) Claims data from dispensing sources also has the added advantage 
that exposure classification is based on dispensed, rather than prescribed, 
prescriptions but however, uncertainty remains as to whether the medication 
was actually used.(73) Neither source captures information on over-the-counter 
exposures including standard dose (400μg) folic acid. 
 
Identification of congenital malformations within healthcare databases is based 
on the presence of medical codes relating to either a diagnosis or treatment for a 
congenital malformation. The level of detail and completeness of the 
information available in these codes varies considerably. In primary care medical 
records, diagnoses made in a hospital setting will only be recorded in the 
database if the patient’s GP chooses to enter the information received from a 
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specialist. Medical codes recorded for the purpose of administrative claims may 
lack detail and accuracy as they are recorded purely for the purpose of creating a 
bill for payment and therefore for the purposes of the database it is the 
procedure, rather than the diagnosis, that is of the greatest importance. Primary 
care medical record databases have the advantage of capturing all types of 
pregnancy outcome including spontaneous abortions and induced terminations 
of pregnancy which are not commonly available within administrative claims 
databases. 
 
Within healthcare databases medical information is routinely recorded 
preventing the need for active follow-up as is required by pregnancy registries. 
Medical record databases have the benefit that an individual can only be lost to 
follow-up if they change GP practice or the GP practice stops contributing data to 
the database. This enables individuals to be followed for many years without any 
additional effort and makes it possible to identify malformations diagnosed later 
in life. Administrative claims databases, however, often have less follow-up time 
as individuals may change insurer when they move jobs or when they become 
pregnant which can reduce the availability of exposure and outcome data for 
research purposes. 
 
Electronic medical records such as the GPRD contain information on smoking, 
alcohol and body mass index (BMI) although this information is not always 
complete and available for every patient.(74) Information on lifestyle factors is 
less likely to be recorded in claims databases,(73) owing to the purpose and 
nature of the database, although there are exceptions like Tennessee Medicaid, 
which contains data on smoking.  
 
One recognised advantage of healthcare databases is the large number of 
individuals and pregnancies that they capture. Contrary to some belief, however, 
small sample sizes can still be a limitation and the ability to identify an 
association in these databases is dependent on the prevalence of the disease 
being studied and the frequency of prescribing.(9)  
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Data sources that capture a representative sample of the population, rather than 
only those with a particular disease or exposure enable the identification of 
multiple internal comparator groups that will have been recruited in the same 
way as those exposed to the product of interest.(9) Depending on the exposure(s) 
of interest, these data sources may still be limited in terms of the number of 
individuals that are eligible for inclusion in any particular control group. 
 
Case-control surveillance systems 
Case-control surveillance systems are purpose-built data sources where cases 
and controls are recruited with the aim of the data being analysed using the 
case-control study design. The efficiency and statistical power resulting from the 
case-control study design are key strengths in enabling these data sources to be 
used to detect increases in risk for rare outcomes and malformation types.  
 
One of the main limitations of case-control surveillance systems is the fact that 
exposure data is collected by maternal self reporting after the pregnancy 
outcome is known. This has the potential to introduce recall bias if there is 
differential reporting of exposure between women who had a pregnancy 
outcome with a congenital malformation and those who did not. In some 
circumstances attempts can be made to control for this by selecting malformed 
controls for the risk assessment studies; either those with chromosomal defects 
or those with a malformation other than the one(s) of interest and thought not 
to be associated with the exposure under study.  
 
Systems that rely on maternal self-reporting do, however, have the advantage 
that they are able to collect data on all types of exposures including those issued 
in a hospital, bought over-the-counter or even borrowed from a friend or 
relative. A further strength is that there is the ability to extend or adapt the 
interview questionnaire to include questions on any potential confounding 
variables that may be associated with the particular exposures and outcomes of 
interest.(57)   
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Case-control surveillance systems either recruit cases of congenital 
malformations directly from hospitals or birth defect registries where they have 
been reported and diagnosed by a paediatrician and often have the benefit of 
access to patient medical records with the mother’s consent. Although some 
systems do capture stillbirths and induced terminations of pregnancy(66) no 
system captures spontaneous pregnancy losses. 
 
Purpose-built case-control surveillance systems have a number of strengths for 
drug safety in pregnancy research but unfortunately they are expensive and 
often trade-offs have to be made in terms of the amount and level of detail of 
information collected and the time and cost required for data collection. There is 
also a need to limit the amount of information requested to minimise the burden 
on participants in order to maximise recruitment. 
 
Other data sources 
In addition to the data sources with systematic data collection outlined in Table 
2.2, the review of the literature identified a number of publications by Teratology 
Information Services (TIS).(75-79) The TIS recruit women who have voluntarily 
contacted them in search of information on the safety of a medicine they have 
used during pregnancy. Women who consent participate in a short telephone 
interview and are given a diary to record any further exposures. They are then 
contacted shortly after the expected date of delivery to obtain information on 
the pregnancy outcome. The voluntary nature of enrolment of women in these 
studies means they are subject to potential selection and self-referral biases and 
often the number of exposures captured for a particular product is small. The TIS 
are, however, valuable signal generating tools and they have the strength that 
information on a large number of potential confounding variables can be 
collected. 
 
The International Clearinghouse for Birth Defects Surveillance and Research 
(ICBDSR) was one source that was identified that did not fit into a single data 
source category.(80,81) The ICBDSR is affiliated with the World Health Organisation 
and aims to bring together a range of data sources being used for birth defect 
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research including congenital anomaly registries, case-control surveillance 
systems and national birth registers. A number of the data sources listed in Table 
2.2 also contribute data and are members of the ICBDSR.(82)  
  
Conclusion 
There is a large number of data sources, in addition to pregnancy exposure 
registries, being used to monitor the safety of medicine use during pregnancy. A 
number of data sources were identified that are currently undergoing review to 
determine their suitability to be used in this kind of research.(68, 69, 70)   
 
When thinking about the extent of evidence available from different studies it is 
important to remember that not all data sources will be capable of capturing all 
exposures. Partly this will be because some sources do not capture exposures in 
hospitals or over-the-counter medicine use but it will also result from differences 
in prescribing practices and the availability of products in different countries.(11) 
It is because of these geographical variations that relatively small surveillance 
systems(70) can be incredibly valuable as a means of monitoring in utero drug 
exposure and its effects.  
 
Few data sources were identified that monitor exposure and pregnancy 
outcomes in less developed countries. The patient characteristics and medicines 
available to pregnant women in these countries are likely to differ considerably 
from other geographical areas and the findings from studies in more developed 
countries may therefore not be generalisable. In recent years attempts have 
been made to develop a pregnancy exposure registry evaluating the safety of 
anti-malarial drugs in malaria-endemic countries(83) but it is likely to be a long 
time before the healthcare systems of many of these countries have an 
automated system that can be utilised for drug safety in pregnancy research. 
 
The fact the data sources identified as part of this review differed in terms of 
their strengths and limitations, highlights the benefit that a combined approach 
using a range of data sources could have in enhancing the extent of information 
available to women and healthcare professionals. It is important, however, that 
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only data sources that contain mostly reliable and accurate information are used 
and it is therefore crucial that a thorough evaluation is carried out of all the 
different aspects involved. This thesis will take one data source, the General 
Practice Research Database, and will evaluate its potential to be used as a tool 
for monitoring the safety of medicines used during pregnancy. The following 
chapter outlines the aims and objectives that will be addressed as part of this 
evaluation. 
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Aim  
Pregnancy exposure registries are commonly used to monitor for major 
teratogenicity following the introduction of a new medicine on the market. Over 
the last fifteen years, however, there has been an expansion in the range and 
number of data sources that are being used for the post-marketing evaluation of 
the safety of medicines when used during pregnancy. In particular, this has 
involved an increase in the use of automated healthcare databases including the 
United Kingdom’s General Practice Research Database (GPRD). Preliminary 
investigations of pregnancy-related research using the GPRD have demonstrated 
its potential to be used in this field of research. These investigations have, 
however, often evaluated different aspects of the database in isolation. This PhD 
aims to evaluate the utility of the United Kingdom’s General Practice Research 
Database to act as an alternative or complement to pregnancy registries in a 
more complete fashion. Given the known teratogenic effects of the older 
anticonvulsant drugs, the large amount of comparison data from anticonvulsant 
pregnancy registries, the chronic nature of epilepsy and the fact the majority of 
treatment will be prescribed within primary care; anticonvulsants were chosen 
for use as a case study. 
 
Objectives 
 
1. The ability to identify pregnancies and pregnancy outcomes is an essential 
requirement of a data source that can be used for drug safety in pregnancy 
research. The first objective was to identify pregnancies in the GPRD within a 
cohort of women with epilepsy. 
 
2. Given the narrow time windows of the different stages of organ and tissue 
development, accurate information on the gestational timing of exposure to 
the product of interest is required. The second objective was to identify, 
within the cohort of women with a diagnosis of epilepsy, those who were 
exposed to anticonvulsants during the first trimester of pregnancy.  
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3. To enable the risk of a pregnancy outcome with a congenital malformation 
following a particular drug exposure to be evaluated, it needs to be possible 
to identify the offspring live deliveries. For the pregnancies identified in 
objective one, the third objective was to link, for live deliveries, the mother’s 
medical record to that of the child.   
 
4. The prevalence of all major congenital malformations is the outcome most 
commonly evaluated by pregnancy exposure registries. The fourth objective 
was to identify, within the cohort of women, all pregnancy outcomes with a 
major congenital malformation. 
 
5. It is important the clinical information available in relation to major 
congenital malformations is accurate, as outcome misclassification can have 
a large impact on the calculated risk estimates. The fifth objective was to 
verify the malformations identified using either full photocopied medical 
records or free text comments recorded by GPs.  
 
6. To assess the reliability of the GPRD as a tool for evaluating drug safety in 
pregnancy, the sixth objective was to compare findings from GPRD data with 
those from a pregnancy registry. To do this, the prevalence of major 
congenital malformations in the cohort of women identified was calculated 
and compared with those reported by the UK Epilepsy and Pregnancy 
Register in 2006.  
 
7. Pregnancy exposure registries aim to detect new teratogens. A number of 
studies have concluded that the anticonvulsant valproate is a teratogen, with 
exposure during pregnancy increasing the risk of a pregnancy outcome with 
spina bifida. The seventh objective of this PhD was to determine whether the 
GPRD can be used to identify a known teratogenic association. To this end I 
focused on first trimester exposure to valproate in monotherapy and an 
increased risk of a pregnancy outcome with spina bifida.  
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8. The inclusion of pregnancies that do not result in a delivery is essential when 
evaluating the safety of a medicine when used during pregnancy. One of the 
advantages of the GPRD is that it captures the full range of pregnancy 
outcomes including spontaneous pregnancy losses and induced pregnancy 
terminations. The final objective was to aid the development of an algorithm 
that in addition to identifying pregnancy losses in the GPRD is also able to 
categorise them in an automated manner into those that were spontaneous, 
induced for a foetal medical condition and induced for other reasons.  
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Chapter 4 
 
The General Practice Research 
Database 
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4.1 An overview of the General Practice Research Database 
 
History 
The General Practice Research Database (GPRD) contains anonymised, 
longitudinal, medical records routinely collected within UK general practice.(1, 2) It 
was originally created in June 1987 as a tool to enable general practitioners (GPs) 
to record information relevant for patient care with the added benefit that the 
data was being held in a central system and could be anonymised and used for 
public health research.(3) After a number of changes in management and 
ownership, the responsibility and management of the database are now with the 
GPRD division of the Medicines and Healthcare products Regulatory Agency 
(MHRA).(1)  
 
Data collection  
The GPRD consists largely of coded data entered onto a computer system by GPs 
as part of the clinical management of patients within general practice. 
Information on patient demographics such as age and sex is also available. When 
a patient visits their GP, the date and type of consultation is recorded using the 
computer software along with information relating to symptoms, clinical 
diagnoses, detailed prescription data and some results of clinical investigations 
and tests. In the UK the GP acts as the gatekeeper to services within the National 
Health Service and therefore in addition to GP consultations the GP may also 
record information relating to hospital or specialist referrals and admissions as 
well as outpatient and emergency visits.(4, 5) Patient anonymisation occurs within 
the GP practice at the point at which the data is downloaded to be transferred to 
the MHRA and results in each patient being assigned a unique identification 
number within each practice. Each GP practice also has a unique GP practice 
number so that the identity of the practices remains confidential.  
 
Medical records 
Data is largely entered onto the database in the form of medical codes. In 1995, 
following the donation of the database to the UK Department for Health, the 
computer software used by participating GP practices changed from a DOS-based 
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to a Windows-based platform. This resulted in a change in the coding system 
used for recording medical symptoms and diagnoses from OXMIS (Oxford 
Medical Information System) codes to Read clinical terms. As of 2007 all OXMIS 
codes entered onto the DOS-based version of the software have been cross-
mapped to Read codes. 
 
In addition to coded data, GPs have the option of recording un-coded comments, 
such as more detailed descriptions of symptoms, diagnoses or treatments along 
with information provided to them via hospital letters and discharge summaries. 
Owing to the need for anonymisation this so called ‘free text’ is not readily 
available to researchers and needs to be requested from the database provider 
at a fee.(6) A large number of studies have been carried out to assess the 
accuracy and completeness of recording in the GPRD for a variety of diagnoses 
and these have been reassuring as estimates of validity have been high.(7, 8, 9)  
Given the wide range of diagnoses recorded in the GPRD there are still, however, 
many diagnoses where no verification assessment has been carried out. 
 
Prescription records 
Prescription data has been found to be reasonably complete in the GPRD and 
this is likely to result from the GP actually needing to use the computer system in 
order to generate a prescription.(4) Prescription information that can be recorded 
within the database includes the date the prescription was written, generic name 
and formulation, strength, quantity, daily dose and the duration of the 
prescription. Although the GPRD has the advantage that prescription information 
is recorded independently by the prescriber, prescription records in the GPRD 
refer only to prescriptions issued and not those that are necessarily dispensed or 
consumed. Over-the-counter medicines are not captured, nor are those that are 
issued during a hospital stay or by a consultant or specialist. Any outpatient 
prescriptions and refills/repeat prescriptions for those initiated in secondary 
care, however, are likely to be handled by the GP and should be captured. 
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Data quality 
The recording of data from each GP practice is subject to quality control checks 
and each practice is assigned an ‘up-to-standard’ (UTS) date, which is the date 
the database provider considered the practice to have started contributing data 
that is of a standard suitable for the purposes of research. At the time of this 
study, assessment of being a UTS practice was based on 10 measures including 
the percentage of ‘acceptable’ patients3; the death, referral and monthly 
prescription rates; the percentage of prescriptions for which a medical indication 
has been recorded and the percentage of referrals with a clinical speciality.(1) 
Each patient is also assigned individual left and right censor dates, between 
which the data within their medical record is considered to be UTS. The left 
censor date (LCENS) is the later of the date the patient joined the practice or the 
date the practice was considered to be providing UTS data. The right censor date 
(RCENS) is the earliest of the date the patient left the practice, the date the 
practice stopped contributing data or was no longer considered to be 
contributing data that was UTS, the date the patient died or the date of the most 
recent data collection. 
 
In general, only data recorded during UTS time periods is considered as eligible 
for inclusion in studies. When a patient registers at a practice for the first time, 
however, GPs may record details of historical medical events they consider 
relevant to the patient’s future medical care, such as the date they were 
diagnosed with a particular medical condition (e.g. epilepsy or diabetes). These 
events will be recorded as occurring before a patient’s LCENS. As GPs are not 
required to repeatedly record diagnoses this may be the only entry of a diagnosis 
within their medical record. Ignoring these records would restrict the study 
population to only those individuals who were diagnosed with a condition whilst 
registered at their current GP practice or had the diagnosis re-entered, so 
depending on the aim of the study and whether there is a requirement for 
                                                             
3
 Those who are permanently registered with a valid first registration date and year of birth, no 
information recorded before the year of birth, a complete and valid transferred out date and 
reason where applicable, ≤115 years of age at end of follow-up and of known or indeterminate 
sex.
(2) 
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incident rather than prevalent cases, there are situations where these records 
may need to be taken into account. 
 
Links to other data sources 
In recent years, attempts have been made by the database provider to link GPRD 
data with that of Hospital Episode Statistics (HES) and the National Cancer 
Registries. Both these links are still in the early stages and are restricted to those 
GP practices that consented to the further linkage (around 40%) and to data 
from 2005 onwards. In the latest GPRD dataset some aspects of the HES data for 
those practices consenting became freely available for the first time. Cancer 
registry data, however, still needs to be requested and these requests are 
assessed on a project by project basis.  
 
Verification services 
The nature of recording in the GPRD means that in some circumstances the 
presence of a single code for a particular condition may not be considered 
confirmation of a diagnosis. There may be scenarios when a GP suspects a 
particular diagnosis and records it in the patient’s medical record but it is later 
diagnostically ruled out but not updated or only updated as a free text 
comment.(9) As a result, the GPRD division at the MHRA offers a number of 
verification services to enable diagnoses identified via the computerised records 
to be confirmed or refuted. For all individuals, regardless of whether they are still 
registered with a GP who contributes data to the GPRD, it is possible to request 
additional anonymised information recorded by the GP in the free text fields as 
mentioned previously. If the patient is still registered with the practice a 
questionnaire can be sent to the GP, or less commonly to the patient 
themselves, to obtain additional information. For patients still registered it is also 
possible to request an anonymised photocopy of the patient’s part or full 
medical record which enables access to all referral and outpatient letters and 
correspondence from consultants and specialists. All these services are available 
at a fee to the researcher and involve going through the GPRD division at the 
MHRA where the content is anonymised. If additional data is not requested it is 
possible to evaluate the reliability of the cases identified by comparing the rates 
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identified in the GPRD with those reported by other data sources. In addition the 
use of algorithms which require supporting evidence (e.g. surgery or the issue of 
a prescription) can also be used in an attempt to minimise case 
misclassification.(7, 9)  
 
Ethical approval 
All studies using the GPRD that are carried out with the aim of publication, or 
communicating results to third parties, must receive International Scientific 
Advisory Committee (ISAC) approval before proceeding. The Multi-center 
Research Ethics Committee (MREC) has given approval for all purely 
observational GPRD studies. Investigators conducting studies that require any 
form of direct patient involvement do, however, need to apply for separate 
MREC approval.(2)  
 
Viewing patients’ medical records 
The Pharmacoepidemiology unit at the University of Bath has developed 
software, referred to as ‘the browser’, which enables researchers to 
view/browse a patient’s electronic medical record in chronological order. 
Reviewing patients’ medical records in this way can prove very valuable for 
getting an overall impression of a patient’s medical condition and the type of 
codes and data that are recorded. It is possible to review all clinical, test and 
therapy records together and also to review records masked to particular 
medical codes and therapy records to ensure that the reviewer makes this 
assessment regarding either exposure or outcome status independent of 
knowledge of the other. This tool has been very beneficial in creating and 
refining algorithms for identifying pregnancies in the GPRD as will become 
apparent throughout this thesis. An example of a patient’s medical record as 
viewed in the browser is shown in Figure 4.1. 
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Figure 4.1 A pregnant patient’s medical record as viewed in the browser 
 
GPRD population 
Since its creation in 1987 the number of patients contributing data to the GPRD 
has gradually grown. As of October 2011 the GPRD contained over 68 million 
person years of data and was actively collecting data on approximately 5 million 
patients (~8% of the UK population) registered at around 630 GP practices within 
the UK.(2) The GPRD contains over 1.5 million pregnancies that ended between 
January 1992 and December 2010 and has the strength of capturing all types of 
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pregnancy outcome including live births, stillbirths, spontaneous abortions and 
induced terminations. Of the pregnancies recorded in the GPRD approximately 
73% result in a delivery and 27% in a pregnancy loss.(10, 11)   
 
4.2 Features of the GPRD specific to drug safety in pregnancy research  
 
When using a database to carry out drug safety in pregnancy research, the 
methods involved in the identification of eligible pregnancies, exposure 
classification and identification of outcomes, differ from those of pregnancy 
exposure registries and case-control surveillance systems. The exact methods are 
also likely to vary depending on the database being used. The next section 
summarises some of the features specific to drug safety in pregnancy research 
using the GPRD. 
 
Identification of pregnancies 
Identifying pregnancies in the GPRD requires the consideration of a large range 
of pregnancy related medical codes including those referring to pregnancy tests, 
the date of the first day of the last menstrual period, estimated date of delivery, 
delivery bookings, antenatal care, pregnancy outcomes including deliveries, 
stillbirths, spontaneous pregnancy losses and induced pregnancy terminations, 
as well as records of neonatal and postnatal care. For the pregnancy algorithm 
developed at the University of Bath, initially all pregnancy related medical codes 
are identified and each code is categorised according to whether it provides 
information on a delivery, a pregnancy loss, the gestational age at pregnancy 
outcome (e.g. premature delivery), a postpartum event or less specific 
supporting evidence of a pregnancy (e.g. an antenatal care record). Each record 
is then assessed in terms of the level of evidence it provides; so for example a 
record of a ‘normal delivery’ would be considered sufficient evidence, whilst a 
female with a record relating to the date of her last menstrual period would 
require additional medical codes providing supporting evidence of a pregnancy. 
All records of a negative pregnancy test are excluded from this process. For 
patients who have a medical record that requires supporting evidence, checks 
are made to ensure an additional code is present within a specified time frame. 
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Once this has been completed, all pregnancy outcome events are identified and 
categorised as being either a delivery (including stillbirth) or a pregnancy loss.(10) 
  
Determining pregnancy end dates 
It is possible that GPs may record duplicate pregnancy outcome records on 
different dates within the GPRD, for example one record on the date of delivery 
and another record when the female attends her six week post-natal visit.  It is 
therefore necessary to estimate the actual pregnancy end date and this is 
important, as will be discussed in the next section, because in many cases it plays 
an essential role in determining the start date of the pregnancy and subsequent 
timings of exposure. The method used at the University of Bath to determine 
pregnancy end dates differs depending on whether the pregnancy resulted in a 
delivery or a pregnancy loss. For pregnancies that ended in a delivery, all 
pregnancy outcome records are listed in ascending date order and the earliest 
delivery event within each group of records for a patient is taken as the end date 
of that pregnancy. For pregnancy loss events, following listing them in ascending 
date order, the last event in a series of six weeks is taken as the pregnancy end 
date. This is because the earlier pregnancy loss codes commonly relate to 
requests and referrals for a termination rather than the date the pregnancy 
actually ended. 
 
Determining pregnancy start dates 
When the outcome of drug safety in pregnancy research is the risk of congenital 
malformations, accurately determining the pregnancy duration and timing of 
drug exposure is crucial given the narrow time window when key foetal 
development takes place and drug exposures have the opportunity to interfere 
and cause adverse effects.(12) For deliveries, where recorded, information on the 
expected date of delivery or the date of the last menstrual period is used to 
calculate the start date of each pregnancy. Where these are not present, the 
algorithm identifies records relating to gestational age (e.g. antenatal care - 32 
weeks) or the existence of a time-related code denoted as premature or post-
mature (e.g. baby premature 36 weeks) and these are used to determine the 
start of the pregnancy. If none of these are recorded, the pregnancy is assigned a 
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default duration of 40 weeks. For pregnancies that end in a pregnancy loss, the 
start date of the pregnancy is determined, where possible, using the same 
method as for the deliveries, however a duration of 10 weeks is assigned where 
no information is available regarding gestational age. 
 
There are some pregnancies in the GPRD where codes that are taken as 
indicative of a delivery (e.g. ‘delivery details’ and ‘birth details’) are recorded 
alongside or in close proximity to codes relating to a miscarriage or spontaneous 
loss. Manual review of a sample of these patients’ medical records in the 
browser made it apparent there were instances where GPs recorded codes that 
could imply the delivery of a live born infant when actually they were recording 
details relating to a pregnancy loss. Where a record for a delivery has a code for 
a spontaneous or induced pregnancy loss within the 42 days before or 21 days 
after, the delivery record is disregarded.  
 
Determining the type and timing of exposure 
Prescription records within the GPRD relate to the issue of a prescription. Given 
the timing of drug exposure is so critical to the identification of possible 
teratogenic effects, it is not considered appropriate to establish exposure status 
based on prescriptions that were issued only during the actual pregnancy. This is 
because a prescription with a 60 day duration issued 15 days before the 
pregnancy start date, if taken in full, will result in the female being exposed 
during the first 45 days of her pregnancy, which is a time when central nervous 
system and cardiac development is already taking place. When determining first 
trimester drug exposure all prescriptions issued in the four to six months before 
pregnancy should also be identified and the exposure mapped based on their 
assumed duration. One limitation of using prescription records, however, is that 
women may decide not to take the medicines if they are trying to become 
pregnant, or once they discover they are pregnant, and using GPRD data it is not 
possible to identify or incorporate this discontinuation. 
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Linking the mother’s record to the child’s record 
To be able to evaluate the safety of medicine use during pregnancy, in terms of 
the risk of congenital malformations in the offspring, it is necessary to link the 
mother’s medical record to the record of the child. In addition to a patient 
identifier, individuals within the GPRD are also given a family number, which is 
primarily based on postal address. For each delivery, attempts are made to link 
the offspring to the mother based on a birth or registration record within the 
same family. Where two females with the same family number have pregnancy 
related codes recorded within two years of the birth, no attempts are made to 
link mother and child. Links were also not attempted where more than one 
possible child existed but with different dates of birth and where the mother 
might be in an institution (family size >20). Within the GPRD it is possible to link 
approximately 80% of all live pregnancy outcomes to a child.  
 
Availability of information on potential risk factors and confounders 
Within the GPRD it is possible to obtain information on a range of variables that 
are either risk factors for congenital malformations or could potentially act as 
confounders within drug safety in pregnancy research. These include maternal 
age, gestational age at pregnancy outcome, parity, gravidity, body mass index, 
alcohol status, smoking status, socioeconomic status, co-morbidities (e.g. 
diabetes) and co-prescribing. The completeness and accuracy of some of these 
variables have not, however, been officially validated. For some patients where 
information is missing it is possible to make assumptions, for example if 
someone was a non-smoker before they became pregnant it is considered 
unlikely that they will have taken up smoking during pregnancy. There are, 
however, a number of individuals who have no data recorded in their medical 
record relating to some or all of these variables and then their status is classified 
as unknown. Within the GPRD there will be some information on family history 
of congenital malformations, however this is thought to be selectively recorded 
and therefore not considered complete enough to provide reliable information. 
Data relating to genetics and over-the-counter prescribing is not available within 
the database. 
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4.3 Overview of drug safety in pregnancy research using the GPRD to date  
 
The first studies that utilised the GPRD for drug safety in pregnancy research 
were published in the late 1990s. Since then a number of studies have been 
published, including papers reporting on methodological aspects of using the 
database in this way. The next section provides a summary of the key papers that 
have been published to date and aims to demonstrate where this PhD fits in 
terms of the broader picture of the GPRD as a tool for the post-marketing 
surveillance of potential new teratogens.  
 
First use of the GPRD for drug safety in pregnancy research 
The first studies to report on pregnancy outcome research using the GPRD were 
published by Jick et al. in the late 1990s.(13, 14) These evaluated exposure to 
anticonvulsants(13) and fluconazole,(14) an antifungal agent, and the associated 
risk of having a child born with a congenital malformation. The methodologies 
reported for both these studies lacked detail on the exact methods of 
determining first trimester exposure and identification of congenital 
malformations. In addition both studies only captured live born pregnancy 
outcomes and had small sample sizes meaning they lacked statistical power. The 
study investigating anticonvulsants was, however, promising in that it found 
100% agreement between data in the computerised medical records on the 
presence of a congenital malformation and the information received from GPs 
following the completion of a questionnaire. These studies were then followed 
by one investigating pregnancy outcomes after intra-uterine exposure to any of 
three acid suppression drugs.(15) The methodology reported was more detailed 
than the papers by Jick et al. but, given what is known about the importance of 
the timing of drug exposure for this kind of research, the study had a wide time 
window of interest (30 days before through to 100 days after LMP). It did, 
however, capture non-live pregnancy outcomes including terminations of 
pregnancy.  
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Methodological studies 
In 2004 the first study focussing on the methodological aspects of using the 
GPRD for drug safety in pregnancy research was published. This paper evaluated 
strategies for identifying pregnancies on the database with a focus on the 
complexity and the vast number of Read/OXMIS codes available for use by 
GPs.(16) This area of research was then also covered by Snowball and de Vries in 
2007(10) who reported that between 1st January 1992 and 29th March 2006 they 
identified 494,449 pregnancies in the GPRD for women aged >11 years at the 
pregnancy outcome date, of which 72.8% resulted in a delivery and 27.2% 
resulted in a termination or miscarriage. In 2010 Devine et al. published a paper 
continuing on the topic of identifying pregnancies in the GPRD.(11) This paper not 
only reported on the creation of a computer based algorithm for identifying 
pregnancies but also on the results of validating the algorithm. The results of the 
validation demonstrated that the algorithm was more successful for live births 
but for other types of pregnancy, such as spontaneous abortions and induced 
terminations, further work was required as it is more difficult to determine 
pregnancy start and end dates when no child’s record exists. Also often multiple 
records relating to a termination of pregnancy (TOP) exist. 
 
Hardy et al. in 2006 went on to evaluate the types of drugs that women in the 
GPRD were prescribed during pregnancy and focussed on those pregnancies 
where it was possible to link the mother to her child.(17) This study captured 
prescriptions received during two time periods; the 90 days before and the 70 
days after the first recorded pregnancy code. Sixty-five percent of women 
received at least one prescription during one of the two time periods. Although 
more work is required to improve the precision of the timing of exposure, this 
study did highlight the large proportion of women within the GPRD who are 
exposed to drugs where the safety of the medication, when used during 
pregnancy, is not fully known.  
 
Identification of congenital malformations 
In 2007, the first research was published looking at the recording and verification 
of congenital malformations in the GPRD with a focus on cardiovascular 
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defects.(18, 19) The first of these two studies compared the prevalence of 
congenital heart defects in the GPRD with two UK population based sources (the 
National Congenital Anomaly System and the UK contributors to EUROCAT)(19) 
and the second study attempted to verify three specific heart defects identified 
in the electronic medical records, using additional information obtained from the 
free text and GP questionnaires.(18) 
 
It was observed that the overall prevalence of congenital heart defects in the 
GPRD was higher than that reported in both of the UK population based sources. 
The authors suggested this could be owing to differences in data collection 
methods and in particular the voluntary nature of reporting by healthcare 
professionals to the UK population based sources. They concluded that the GPRD 
should capture the majority of cases for the population covered and has the 
advantage of including minor malformations that may not always be reported to 
the national registries. They also reported that the extended period of follow up 
in the GPRD is an advantage over sources such as EUROCAT, which although 
accept malformations diagnosed at any age, tend to focus on those diagnosed 
within the first year of life.(19) 
 
In the verification study(18) there was a 93.5% positive predictive value between 
the computerised records and responses to the GP questionnaires. This ranged 
from 90% for Tetralogy of Fallot to 100% for coarctation of the aorta. Fifty-one 
percent of infants were found to have free text comments in their medical 
records that provided additional information such as the findings from 
echocardiograms and past or future surgery. The authors concluded that the 
computerised medical records within the GPRD were suitable for studying the 
occurrence of these particular heart defects, but that where possible all infant 
free text attached to a malformation diagnosis should be requested to obtain as 
much detail as possible.  
 
Similar research was published in 2008, this time focussing on neural tube 
defects (NTDs).(20) Owing to the nature of this class of defect this study included 
diagnoses of malformations that resulted in a termination of pregnancy, in 
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addition to those found in live and stillbirths. An algorithm was developed to 
identify new cases of NTDs in the GPRD in either the mother’s or the child’s 
record. The identified cases were then verified using GP questionnaires. The 
study identified 217 unique NTD cases; 148 recorded in the mother’s record and 
69 in the child’s. Of the 169 questionnaires that were returned 117 (71%) NTD 
cases were verified. The positive predictive value (PPV) of the algorithm was 
found to vary by NTD diagnosis and ranged from 0.81 for anencephaly to 0.47 for 
spina bifida. The authors reported that the low PPV for spina bifida could have 
resulted from the inability of the algorithm to differentiate between cases where 
the mother herself had spina bifida and cases where it was present in the foetus 
or child. The annual prevalences of NTDs in the GPRD were comparable to those 
of the National Congenital Anomaly System in later years, but slightly higher in 
the early years. The authors concluded NTDs can be identified in the GPRD, 
therefore the GPRD provides an opportunity to evaluate maternal exposures and 
this severe class of congenital malformation. It was proposed that searching the 
free text comments or sending out a more comprehensive questionnaire may be 
required in order to minimise the false positives identified for cases of spina 
bifida.  
 
Potential of the GPRD as a tool for post-marketing teratogen surveillance 
In 2008 Charlton et al. published the paper referred to earlier which reported on 
the mean number of annual exposures to a range of drugs during pregnancy 
captured in the GPRD and made comparisons with the numbers enrolled in 
pregnancy exposure registries.(21) This study found the GPRD has a potential role 
in the field of drug safety in pregnancy research and that for more prevalent 
conditions, such as depression, the GPRD should capture a similar mean annual 
number of exposures as a pregnancy registry. Since then, to our knowledge one 
manuscript has been published that reported on congenital malformations as an 
outcome following a relatively common exposure.(22) For drugs used to treat a 
disease with a relatively low prevalence and for those new on the market, 
however, pregnancy exposure registries were found to capture more exposures.  
 
 70 
This brief review of the papers published to date has demonstrated that work is 
continuously ongoing in relation to using the GPRD for drug safety in pregnancy 
research. Over the last 10–15 years several attempts have been made to assess 
the reliability of the GPRD as a tool for post-marketing teratogen surveillance, in 
addition to trying to improve the quality and robustness of study findings. To 
date, however, the majority of work has been carried out to evaluate different 
aspects of the database in isolation and has focussed on either the 
methodological aspects of identifying pregnancies on the database or has been 
limited to the verification of a small number of specific congenital 
malformations. The work presented in the rest of thesis aims to evaluate all 
aspects of the GPRD relevant to drug safety in pregnancy research in 
combination. This will be done by conducting a risk assessment study and for the 
reasons outlined in the next chapter, uses anticonvulsants as a case study. 
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Chapter 5 
 
Anticonvulsants as a case study 
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Anticonvulsants are widely used for the treatment of epilepsy in addition to 
other conditions including bipolar disorder and neuropathic pain. As will be 
discussed below, there are several reasons why this class of drug has been 
extensively monitored by multiple pregnancy exposure registries and is 
considered a suitable case study for this PhD.  
 
5.1 Treatment of epilepsy 
Epilepsy is a medical condition that is defined as “a disorder of brain function 
characterised by recurrent seizures that have sudden onset”.(1) In approximately 
75% of individuals, general control of epilepsy is achieved by taking 
anticonvulsant drugs.(2) The broad spectrum of epileptic seizures and the fact 
they can occur anywhere in the brain, means there are a large number of 
different anticonvulsant products; each one often being more effective in 
treating some seizure types than others. In addition, not all individuals obtain 
sufficient seizure control from a single anticonvulsant and in approximately 20% 
of cases polytherapy treatment with a combination of anticonvulsant drugs is 
required. Given the likelihood of recurrent seizures and the potential harm these 
can cause to the individual, it is often inadvisable to stop anticonvulsant 
treatment. It is this inability to discontinue treatment that has a number of 
implications for women of child-bearing age. 
 
5.2 Epilepsy and pregnancy 
The incidence of epilepsy is highest in the first decade of life with a second peak 
occurring in those over 60 years of age.(3) Although some individuals do not 
experience seizures as an adult and only suffer from childhood epilepsy, the 
young age at onset means that approximately a quarter of individuals with 
epilepsy are women of child bearing age.(4)  The number of pregnancies reported 
in the literature to be to women with epilepsy ranges from 3-6 per 1000(5-7)  
depending on the country of study and whether stillbirths and pregnancy losses 
are included. In the UK, approximately 2,500 women with epilepsy will have a 
baby each year.(8) 
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There is some uncertainty over the role epilepsy as a condition plays in terms of 
being a risk factor for adverse pregnancy outcomes. As the number of women 
with epilepsy not prescribed anticonvulsants is small, and they may not choose 
to enrol in a registry, the effect of epilepsy itself is difficult to determine. A meta-
analysis of ten studies that had captured a total of 400 women with epilepsy 
unexposed to anticonvulsants found no evidence to suggest epilepsy itself is 
associated with an increased risk of major congenital malformations when 
compared to non-epileptic controls.(9) As women with untreated epilepsy are 
likely to have a less severe form of the disease and will also have better seizure 
control, questions remain over the comparability of women with treated and 
untreated epilepsy(10) and given these differences, it is difficult to evaluate with 
any certainty the role of epilepsy severity and seizures on the risk of a pregnancy 
outcome with a major congenital malformation.  
 
5.3 Anticonvulsant exposure and pregnancy outcomes 
Post-marketing studies have shown that exposure during the first trimester of 
pregnancy, to the older generations of anticonvulsants, is associated with a two- 
to three-fold increased risk of a pregnancy outcome with a major congenital 
malformation, when compared to the risk in the general population.(11, 12) The 
risk of congenital malformations has also been found to be higher in women 
exposed to polytherapy anticonvulsant treatment compared to those taking 
monotherapy.(11) In addition, studies have shown evidence of a dose response 
relationship associated with some anticonvulsants, with the risk of a congenital 
malformation increasing with increasing daily dose.(11,13,14) In recent years, 
studies evaluating the effect of maternal anticonvulsant exposure on the 
neurodevelopment of the infant have found evidence that infants exposed in- 
utero to valproate or carbamazepine are more likely to have impaired cognitive 
function and developmental delay than those unexposed or taking other 
anticonvulsants such as lamotrigine.(15, 16) As a result of all these factors, women 
with epilepsy who are considering becoming pregnant, are recommended to 
seek advice so attempts can be made to ensure they are on the optimum 
treatment regimen and exposed to the minimum number of anticonvulsants at 
the lowest effective dose.(17, 18) Some enzyme inducing anticonvulsants, such as 
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carbamazepine and phenobarbital, however, have been found to interact with 
and reduce the effectiveness of hormonal contraceptives.(4) This therefore has 
the potential to increase the likelihood of an unplanned pregnancy if alternative 
or additional methods of contraception are not used.   
 
Even when pregnancies are planned, it is not always possible for women to 
switch to what is considered to be a safer product or lower dose. For example, a 
study by the EURAP Epilepsy and Pregnancy Register found the percentage of 
women who were seizure-free during pregnancy was lower in women taking 
lamotrigine monotherapy compared to valproate monotherapy.(19) When making 
decisions about prescribing anticonvulsant therapy to women who are planning 
to become pregnant, it is important to balance the risks of potential adverse 
pregnancy outcomes with the benefits of having adequate seizure control. This 
is, however, complicated by the limited amount of information that is available 
on the teratogenic potential of some of the newer anticonvulsants owing to 
often small sample sizes in follow-up studies/pregnancy registries. 
 
Of the older anticonvulsants, valproate and carbamazepine are the most 
commonly prescribed although both are associated with an increased risk of 
neural tube defects and in particular spina bifida. The risk of spina bifida 
following first trimester exposure to valproate is approximately 2%(13,20) and 
following carbamazepine exposure is 1%(21) compared to 0.1% in the general 
population. Studies in the general population and women who have previously 
had a pregnancy with a neural tube defect, have demonstrated that folic acid 
supplementation before and during the early stages of pregnancy is effective in 
reducing the risk of a pregnancy outcome with a neural tube defect.(22,23) As a 
result all women planning to become pregnant, regardless of anticonvulsant 
exposure, are recommended to take 400mcg of folic acid daily before conception 
and until week 12 of pregnancy. Women considered to be at an increased risk, 
who have a history of a pregnancy or family member with a neural tube defect, 
are recommended to take a higher daily dose of 5mg. As some anticonvulsants 
including carbamazepine, phenytoin and phenobarbital are folic acid 
antagonists(24) women on anticonvulsant therapy are also recommended to take 
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the higher 5mg daily dose of folic acid before and during the first trimester of 
pregnancy.(25) The extrapolation of the protective and beneficial effect of folic 
acid supplementation in the general population to women taking anticonvulsants 
has, however, been questioned. A number of studies(24, 26, 27) and case-reports(28) 
evaluating the effect of folic acid exposure early on in pregnancies exposed to 
anticonvulsant therapy have reported that they did not observe a reduction in 
the risk of neural tube defects and other congenital malformations where folic 
acid is thought to reduce the risk. It is therefore possible that the teratogenic 
effect of anticonvulsants is associated with a different mechanism to that 
associated with the folate metabolism. As folic acid supplementation is not 
known to be associated with any harmful effects in women of childbearing age, 
women taking anticonvulsant therapy are however, still recommended to take 
5mg daily. 
 
5.4 Pregnancy exposure registries for anticonvulsants  
The increase in risk of major congenital malformations associated with exposure 
to the older anticonvulsants, the inability to discontinue treatment and the 
potential for inadvertent exposure during pregnancy, make new anticonvulsant 
drugs ideal candidates for monitoring by pregnancy exposure registries. The 
introduction of the anticonvulsant lamotrigine in 1992 saw the creation of the 
first pregnancy registry for an anticonvulsant exposure.(29) This was then 
followed by several pregnancy exposure registries that were set up in the mid to 
late 1990s to recruit and capture pregnancies exposed to any anticonvulsant 
product.(11, 30-32)  
 
Over time these pregnancy exposure registries have captured a large amount of 
data on anticonvulsant exposure during pregnancy and in some cases have 
confirmed and provided further supporting evidence for the increased risks 
associated with first trimester exposure to the older anticonvulsants.(13) For the 
newer anticonvulsants, however, many of these registries are still limited in 
terms of the number of first trimester exposures enrolled for which they have 
informative outcome data. When evaluating anticonvulsant exposure, identifying 
a sufficient number of exposures is further restricted by the fact that around 20% 
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of women take more than one anticonvulsant as polytherapy, making it 
impossible in these cases to determine any causal association between an 
individual drug and congenital malformation risk. The variations in data 
collection methods, in terms of inclusion and exclusion criteria, timing of 
enrolment, outcome definitions, duration of follow-up and the fact that some 
pregnancies may be reported to multiple registries means that it is considered 
inappropriate to pool data from the different registries to increase sample 
sizes.(33) 
 
In 2006 the North American Antiepileptic Drug Registry generated a signal 
associated with first trimester monotherapy exposure to lamotrigine and a 10-
fold increased risk of isolated oral clefts (RR 10.4; CI95 4.5-24.9). Following this 
signal, data from other pregnancy registries were analysed and studies in the 
literature reporting on first trimester exposures to lamotrigine were also 
reviewed. None of these data sources, however, could provide sufficient 
evidence to either confirm or refute the association.(34) As a result, 
GlaxoSmithKline, the manufacturer of lamotrigine, decided to continue 
surveillance with the different pregnancy registries whilst also conducting a case-
control study using data collected by the EUROCAT network; a network of 
population based congenital anomaly registers which cover around 25% of all 
births in Europe.(34, 35) This case-control study did not find evidence to confirm 
the large increase in risk identified by the North American Registry. Given the 
small numbers, however, it was not possible to rule out anything smaller than a 
three-fold increase in risk and therefore continued surveillance was 
recommended.(34)  It is not clear why the North American Registry came up with 
such a large association that could not be reproduced elsewhere. Oral clefts can 
run in families and it is possible that the voluntary nature of enrolment to the 
registry means women who have already given birth to a child with an oral cleft 
are more likely to choose to enrol for a subsequent pregnancy. The authors do 
mention that the prevalence of isolated oral clefts and particularly cleft palate in 
the population they used as a comparator group was lower than many other 
data sources. They did demonstrate, however, that when applying these higher 
comparator figures, although the risk is lowered, the significant increase in risk 
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did not go away. It will therefore be interesting to see what findings future 
studies with the advantage of larger sample sizes produce. 
 
In recent years two pregnancy registries have reported findings suggestive of an 
increased risk of major congenital malformations associated with first trimester 
exposure to topiramate.(36, 37) In 2008, the UK Epilepsy and Pregnancy Register 
reported a major congenital malformation prevalence of 4.8% and 11.2% 
following mono and polytherapy exposure to topiramate respectively.(36) It was 
also reported that the rate of oral clefts for all topiramate exposed pregnancies 
(N=203) was eleven times the background rate (2.2%; 95% CI 0.9 to 5.6%). This 
study also reported 4 cases of hypospadias within 78 male live births (5.1%; 95% 
CI 0.2 to10.1), although only 2 of the malformations were severe enough to be 
classed as major and only one of those was exposed to topiramate as 
monotherapy.(36) Following these findings a study was conducted using data 
collected by the North American Antiepileptic Drug Pregnancy Register.(37) This 
study identified 289 first trimester monotherapy exposures and it identified a 
higher prevalence of major malformations following topiramate exposure 
compared to the unexposed control group of friends and family members (3.8 v 
1.3%). It also identified an increased risk of isolated cleft lip compared with the 
expected background prevalence (0.69 v 0.07%). The results of the latter study 
informed the FDA’s decision to change the safety categorisation of topiramate 
use during pregnancy from category C to category D (Table 5.1). Both studies, 
however, concluded that the findings were based on small numbers and further 
studies were required to determine whether there is evidence of a true causal 
association. 
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Table 5.1 Categories used by the US Food and Drug Administration to summarise the 
safety of medicines used during pregnancy based on the available evidence(38) 
 
Category Description of evidence 
A Adequate and well-controlled studies have failed to demonstrate a risk to the 
fetus in the first trimester of pregnancy (and there is no evidence of risk in 
later trimesters). 
B Animal reproduction studies have failed to demonstrate a risk to the fetus and 
there are no adequate and well-controlled studies in pregnant women. 
C Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential 
benefits may warrant use of the drug in pregnant women 
D There is positive evidence of human foetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but 
potential benefits may warrant use of the drug in pregnant women despite 
potential risks. 
X Studies in animals or humans have demonstrated foetal abnormalities and/or 
there is positive evidence of human foetal risk based on adverse reaction data 
from investigational or marketing experience, and the risks involved in use of 
the drug in pregnant women clearly outweigh potential benefits. 
 
 
The lamotrigine and topiramate examples demonstrate that pregnancy exposure 
registries are effective at generating potential safety signals but not every signal 
is evidence necessarily, of a causal association between exposure and outcome. 
When evaluating the risks associated with specific defect types, however, sample 
size within these registries can be a major limitation both in terms of the time 
taken to generate a signal and the statistical power available to determine an 
increase in risk with any level of certainty. Over time the increase in the number 
of pregnancies exposed to newer anticonvulsants, or any new product, is 
inevitably going to lead to an increase in the number of signals generated in 
relation to a potential major congenital malformation risk. It is important that 
potential signals are identified as soon as possible following a product’s 
introduction on the market and that any signals are confirmed or refuted 
promptly to reduce unnecessary concern and confusion. It is therefore important 
that all potential data sources that could potentially play a role in achieving this 
are comprehensively evaluated. The amount of comparison data available on 
anticonvulsant exposures combined with the chronic nature of the disease and 
most repeat anticonvulsant prescribing taking place in UK primary care makes 
anticonvulsants a suitable case study for investigating the potential of the 
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General Practice Research Database as a tool for drug safety in pregnancy 
research.  
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Identifying major congenital 
malformations in the UK General 
Practice Research Database  
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6.1 Introduction 
The UK General Practice Research Database (GPRD) is the world’s largest 
computerized database of anonymised, longitudinal medical records from 
primary care,(1) and has the potential, in some circumstances, to aid research into 
the safety of medicines used during pregnancy.(2) Work has begun to validate the 
recording of congenital malformations in the GPRD, although to our knowledge 
thus far it has been limited to a selection of cardiovascular defects(3) and neural 
tube defects.(4) 
 
This paper forms part of a broader study to assess the potential of the GPRD to 
act as a pregnancy registry system focusing on a cohort of women with a 
diagnosis of epilepsy, seizure or convulsion. Here we describe the methodology 
used for the surveillance of the range of congenital malformations that would be 
required if the GPRD is to be used to monitor drug safety in pregnancy. We 
report the extent to which diagnoses identified in the GPRD could be confirmed, 
rejected or made more specific by using the photocopied paper medical  records 
or where this was not possible any data entries consisting of uncoded comments, 
so-called ‘free text,’ in the GPRD, which are not routinely available for research 
purposes.  
 
6.2 Methods 
6.2.1 Data source 
The GPRD contains over 44 million person-years of data and currently captures 
data from ~4 million active patients (~7% of the UK population).(5) Virtually all 
prescriptions, non-drug interventions and referrals issued by general 
practitioners (GPs) are recorded in the database, as are medical diagnoses, 
including those relating to pregnancy. The database is managed by the GPRD 
division at the Medicines and Healthcare products Regulatory Authority (MHRA), 
who also provide a number of services to allow verification of events and 
diagnoses identified from the computerized records. For patients still registered 
at the GP practice it is possible to request anonymised photocopies of the 
patient’s full paper medical record, enabling access to all referrals and out-
patient letters and correspondence from consultants and specialists. For all 
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patients, regardless of whether they are still registered with the GP practice, it is 
possible to request the information recorded by GPs as free text in the electronic 
GPRD record. GPs have the option of recording free text comments, i.e. uncoded 
additional information relating to symptoms, more detailed diagnoses, test 
results, etc., each time they record a medical code within the database. It is 
recommended that these verification services are used to assess the sensitivity 
and specificity of medical codes.(1) All methods of verification are requested via 
the GPRD group at the MHRA to ensure that both practice and patient 
confidentiality are maintained.  
 
6.2.2 Study population 
Women were eligible for inclusion if they were, or had been, permanently 
registered at a GP practice regarded by the MHRA to be contributing data up to 
research standard. Women were included in the analysis of verification of major 
congenital malformation codes within the child’s record if they had a medical 
record indicating a live pregnancy outcome between 1 January 1990 and 31 
December 2006 and they had a code relating to a diagnosis of epilepsy, seizure 
or convulsion.  
 
Women were excluded from the cohort if they were not 14–49 years of age at 
the date of delivery and if they did not have a code indicating a pregnancy in the 
280 days leading up to the delivery date. In view of requirements for the broader 
study, women were also excluded if they were not continuously enrolled in the 
GPRD for the 4 months before the estimated date of the last menstrual period or 
if the diagnosis of epilepsy, seizure or convulsion was not before the pregnancy 
indicator code.  
 
The offspring of women meeting all inclusion criteria were identified where 
possible (based on having the same family and GP practice numbers and the 
child’s year and month of birth being equal to the mother’s year and month of 
delivery). Mother-baby pairs were included if the linked child was registered and 
present in the GPRD 3 months after the mother’s pregnancy outcome date. If the 
child had been registered and died before reaching 3 months of age the mother-
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baby pair was still included and the need to be registered 3 months after the 
pregnancy outcome date was no longer required. Women were entitled to 
contribute more than one mother-baby pair to the study and each unique 
offspring was considered separately. 
 
6.2.3 Identification of major congenital malformations 
To identify individuals with a major congenital malformation, search terms for all 
congenital malformations were created based on those listed in the International 
Classification of Diseases 9th edition(11) ‘congenital anomalies’ chapter (ICD-9 
codes 740–759). These search terms contained ‘wild cards’ to allow for variations 
in terms, e.g. ‘hydroceph*’ to account for ‘hydroceph-aly’ and ‘hydroceph-alus’. 
All medical codes containing these search terms were then selected plus any 
relevant codes identified by being in their hierarchical vicinity. Children of 
women in the cohort were then identified in the GPRD if they had any of these 
codes within their medical record.  
 
As pregnancy registries are primarily concerned with major malformations, the 
malformations identified were categorized as major or minor based on the 
information available through the Read and OXMIS codes used in the GPRD, 
photocopied medical records and free text. This categorization was based on the 
classification used by the European network of population-based registers for 
the epidemiological surveillance of congenital anomalies (EUROCAT). Minor 
defects and malformations associated with prematurity, when isolated, are 
excluded from EUROCAT reports. In addition, there are some malformations (e.g. 
hypospadias, hydronephrosis, talipes, syndactyly) that are only classified as 
major if certain criteria are met.(6,7)  
 
All congenital malformation codes identified within the cohort were reviewed 
independently by two of the authors (RC, JW). Those relating to a major 
malformation and those relating to a malformation that could be classed as 
major, if specific criteria were met, were selected for verification. 
 
 
 87 
6.2.4 Verification of congenital malformations 
Verification of congenital malformations was carried out by requesting a 
photocopy of the child’s entire medical record for children still registered with 
the practice. These were then reviewed to ensure that the congenital 
malformation recorded in the computerized medical record was a true 
malformation and had been correctly coded. Secondly, for those malformations 
that needed to meet specific inclusion criteria in order to be classified as major, 
information relating to this was identified, where present, enabling the true 
number of major malformations to be determined. Photocopied medical records 
were requested via the MHRA, who sent out an initial request and three 
subsequent reminders to GPs at fortnightly intervals. For children who had 
transferred out of the practice and for those where the GP did not return 
photocopied records, all the information recorded in the free text within the 
child’s entire electronic GPRD medical record was obtained and reviewed.4 One 
example recorded alongside a code for an oral cleft included: “Right cleft lip – 
admit ***, repair cleft lip under GA, Hare lip palate intact.” All information in the 
photocopied medical records and free text was anonymised by the MHRA before 
being transferred to the investigators.  
 
6.2.5 Analyses 
The percentage of diagnoses identified from the computerized records that 
could be confirmed as being the congenital malformation recorded was 
calculated for the photocopied medical records and free text verification 
methods separately and combined. Of those malformations that were 
confirmed, the percentage where sufficient information was available to classify 
as a major or minor congenital malformation was then calculated both overall 
and for different subgroups of congenital malformations. As we did not request 
photocopied medical records or free text for those individuals who were not 
identified as having a major congenital malformation, it was not possible to 
calculate the specificity of the computerized records. 
 
                                                             
4 
It is not possible to obtain photocopied records for patients who have transferred out of the 
  practice. 
 88 
6.3 Results 
6.3.1 Verifying the presence of a congenital malformation 
The study population consisted of 3869 live births within this cohort of women 
with a record of epilepsy, seizure or convulsion any time before the pregnancy. 
188 potentially major congenital malformations recorded at any age were 
identified relating to 161 unique individuals. Photocopied medical records were 
requested for the 123 individuals (76.4%) still registered with the practice. Figure 
6.1 shows the response to the photocopied record requests, with 96 records 
(78.0%) being returned, relating to 109 unique malformations. In addition, the 
GPs of 12 individuals (9.8%) replied to explain why they were not enclosing the 
photocopied records.  
 
 
 
Figure 6.1 Methods used for verifying malformations 
 
Still registered with the practice so 
requested full photocopied medical records 
 
123 individuals (76.4%) 
141 MCMs 
No longer registered with the 
practice so requested free text 
 
38 individuals (23.6%) 
47 MCMs 
Received photocopied 
records 
 
96 individuals (78.0%) 
109 MCMs 
GP responded but no 
records sent 
 
12 individuals (9.8%) 
15 MCMs 
No response to record 
request 
 
15 individuals (12.2%) 
17 MCMs 
Requested free text 
 
25 individuals 
30 MCMs 
Total free text 
requested 
 
63 individuals 
77 MCMs 
 
No MCM information provided: 
4 x GP or practice will not participate 
1 x No records held 
2 x No longer use Vision
† 
1 x Child has left practice 
1 x Wanted parental permission 
1 x Parents refused permission 
 
MCM information provided: 
1 x GP states: no MCM 
1 x GP states: wondered about mild 
hydronephrosis prenatally but all normal at 
6 week scan 
188 potentially major congenital malformations 
(MCMs) relating to 161 unique individuals 
†  
The GP practice software that feeds into the GPRD;  MCM = major congenital malformation
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For 15 individuals (12.2%) the GP did not respond to the record request and 
therefore free text was obtained. Free text was also obtained for the ten cases 
where the GP responded but did not provide additional information on the 
potential major congenital malformation and for the 38 individuals no longer 
registered with the practice. In total, free text was therefore obtained for 63 
individuals (39.1%) representing 77 major congenital malformations. Figures 6.2 
and 6.3 along with Table 6.1 summarise the percentage of malformations that 
could be confirmed (i.e. verified) or refuted as a congenital malformation, and 
the percentage of those confirmed that could be further classified as being major 
or minor.  
 
 
 
Figure 6.2 Percentage of congenital malformations that could be verified using  
photocopied records and of those the percentage that could be classified as major or  
minor. Major/minor classification was based on that used by EUROCAT.  
 
 
 
 
Not a congenital malformation: 
 
5 malformations  (4.6%) 
Verified - congenital malformation: 
 
100 malformations  (91.7%) 
 
 
Not enough information: 
 
4 malformations  (3.7%) 
1 x Dislocation of hip 
1 x Hypospadias 
1 x Talipes unspecified 
1 x General malformation 
code 
 
1 x Craniosynostosis 
1 x Anophthalmos  
1 x Dislocation of hip 
1 x Talipes unspecified 
1 x General malformation code 
 
Minor congenital malformation: 
 
15 malformations (15.0%) 
Major congenital malformation: 
 
78 malformations  (78.0%) 
Not enough information: 
 
7 malformations (7.0%) 
2 x Talipes unspecified 
1 x Talipes equinovarus 
2 x Syndactyly 
1 x Patent ductus arteriosus 
4 x Hypospadias 
3 x Hydronephrosis 
1 x Dislocation of hip 
1 x General malformation code 
 
2 x Syndactyly 
2 x Hypospadias 
2 x Hydronephrosis 
1 x Short leg congenital 
Received photocopied medical records for: 
           - 96 unique individuals 
           - 109 potential major congenital malformations 
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Figure 6.3 Percentage of congenital malformations that could be verified using free text 
and of those the percentage that could be classified as major or minor. Major/minor 
classification was based on that used by EUROCAT. 
 
Using a combination of photocopied medical records and free text it was possible 
to verify 160 malformations (85.1%) as the malformation indicated by the 
computerized records. For those where photocopied records were available, the 
percentage verified was 91.7% (100/109) and for those where the free text was 
used it was possible to verify 77.9% of malformations (60/77). Nine cases (4.8%) 
in total were found not to have the malformation recorded; these included seven 
cases of diagnostic suspicion that were not confirmed on investigation and 
where computer records were not updated, one case where the GP wrote in 
response to receiving the request for photocopied medical records to state that 
the infant did not have a major congenital malformation and one case where an 
incorrect code had been recorded. Using photocopied medical records it was 
possible to either confirm or refute the presence of a malformation in 96.3% of 
cases (105/109) and in 80.5% of cases (62/77) using the free text.  
Not a congenital malformation: 
 
2 malformations  (2.6%) 
Verified - congenital malformation: 
 
60 malformations  (77.9%) 
 
 
Not enough information: 
 
15 malformations  (19.5%) 
1 x Congenital cataract 
2 x Dislocation of hip 
1 x Limb reduction 
1 x Oral cleft 
1 x Patent ductus arteriosus 
1 x Pulmonary stenosis 
2 x Syndactyly 
2 x Talipes unspecified 
4 x Ventricular septal defect 
 
1 x Talipes unspecified 
1 x Equinovarus 
 
Minor congenital malformation: 
 
9 malformations (15.0%) 
Major congenital malformation: 
 
47 malformations  (78.3%) 
 
Not enough information: 
 
4 malformations (6.7%) 
2 x Patent ductus arteriosus 
2 x Hypospadias 
4 x Talipes unspecified 
1 x General malformation code 
 
2 x Hypospadias 
1 x Talipes unspecified 
1 x Talipes equinovarus 
Received free text for: 
- 63 unique individuals 
- 77 potential MCMs 
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Table 6.1 Percentage of congenital malformations that could be verified and, of those, the percentage that could be classified as major or minor  
 
Verification method Number of 
malformations 
Outcome of verification of congenital 
malformations identified by medical codes in the 
GPRD [n (%)] 
Verified congenital malformations that 
could be classified as major or minor 
(n = 160) [n (%)] 
  yes (a 
malformation) 
no (refute, 
incorrectly coded) 
not enough 
information 
major minor not enough 
information 
Photocopied medical 
recordsb 
109 100 (91.7)  5 (4.6)    4 (3.7)    78 (78.0) 15 (15.0)    7 (7.0)  
Free textc   77   60 (77.9)  2 (2.6)  15 (19.5)    47 (78.3)     9 (15.0)    4 (6.7)  
Both methods combineda  188a  160 (85.1)  9a (4.8)  19 (10.1) 125 (78.1) 24 (15.0)  11 (6.9) 
a
 Includes the two cases where the general practitioner wrote to say that there was no malformation but did not send photocopied medical records and free text was not  
  requested. 
b
 Anonymised photocopies of the patient’s full paper medical record, enabling access to all referrals and out-patient letters and correspondence from consultants and  
  specialists. 
c
 Anonymised uncoded additional information, i.e. relating to symptoms, more detailed diagnoses, test results, etc. recorded by the general practitioner in the patient’s 
 computerised medical record.  
GPRD = General Practice Research Database. 
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Table 6.2 demonstrates that the verification of the presence of a congenital 
malformation varied by malformation class. It was possible to verify all CNS, 
digestive system, chromosomal and foetal valproate syndrome anomalies. 
Within the majority of other malformation classes, with the exception of talipes, 
congenital dislocation or dysplasia of the hip and anomalies of the eye, 
verification was found to be over 80.0%. 
 
6.3.2 Classifying as a major or minor congenital malformation 
Table 6.1 shows that of the 160 verified congenital malformations, it was 
possible to classify 93.1% (149) as being major or minor. This percentage was 
found to be the same for those cases reviewed by photocopied medical records 
and those reviewed using free text. For 125 cases (78.1% of those verified), 
review of the photocopied medical records or free text resulted in the 
malformation identified on the computerized records being classified as major, 
whilst 24 cases (15.0%) were classified as minor. For the remaining 6.9% (11/160) 
of verified malformations there was insufficient information to classify them as 
being major or minor. Of the 188 congenital malformations initially identified, 
125 (66.5%) could be both verified as a malformation and classified as being 
major, which is what would be of primary interest to pregnancy registries.  
 
The percentage of verified congenital malformations that could be classified as 
major was found to vary by malformation class (Table 6.2). For many classes of 
malformation the percentage that could be classified as major was ≥80.0%. This 
was, however, lower for those classes that included malformations needing to 
meet specific inclusion criteria (e.g. hydronephrosis, hypospadias, syndactyly, 
talipes, patent ductus arteriosus) to be classified as being major (e.g. talipes – 
where cases of a postural origin were excluded from the major malformation 
count).  
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Table 6.2 The number of congenital malformations that could be verified, and of those the number that could be classified as major, by malformation class 
 
Malformation class Number of 
malformations 
Outcome of verification of congenital malformations 
identified by medical codes in the GPRD (n) 
Of the verified congenital 
malformations the number that could 
be classified as major or minor (n) 
  Yes, 
a malformation  
No, refute, 
incorrectly coded  
Not enough 
information  
Major  Minor  Not enough 
information  
Central nervous system 5 5  0 0   5    0    0 
Congenital heart defects 50 44  0 6  41    3    0 
Orofacial clefts 7 6  0 1      6    0   0 
Eye 4 2  1  1       2    0   0 
Digestive system 6 6  0 0      6    0   0 
Internal urogenital system 23 22  1  0   17    3    2  
Hypospadias 28 27  0 1    17    6    4  
Talipes 18 12  3  3      4    6    2  
Hip dislocation/dysplasia 16 11  2  3    10    1    0 
Poly-/syndactyly 10 8  0 2      4    2    2  
Limb reduction 6 5  0 1      4    0   1  
Musculoskeletal 1 0 1  0  NA NA NA 
Chromosomal 1 1 0 0     1 NA NA 
Foetal valproate syndrome 4 4  0 0     4    0   0 
Other 9 7  1  1      4    3    0 
Total 188 160 9 19 125 24 11 
NA = not applicable; GPRD = General Practice Research Database.  
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6.4 Discussion 
This study indicates that a wide range of congenital malformations can be 
identified reliably using the GPRD. The presence or absence of a malformation, 
regardless of whether major or minor, was confirmed in 85.1% (160/188) of 
those identified using the computerized records. In infants for whom 
photocopied medical records were received, it was possible to confirm or refute 
96.3% of recorded malformations. The overall verification rate was lowered by 
the review of some cases being limited to information in the free text, but this 
resulted largely from the study covering a retrospective 16-year time period. Had 
the study been carried out in real-time following a drug being launched on the 
market, or had a review been carried out at frequent intervals, then photocopied 
medical records would have been available for a larger proportion of individuals, 
probably resulting in higher verification rates.  
 
At 78.1%, the overall verification and classification of major malformations 
within this cohort of individuals in the GPRD compares favourably to that found 
by Cooper et al.(10) using Tennessee Medicaid computerized records. They found 
that 67.7% of all major congenital malformations identified by birth certificates 
or patient claims could be confirmed by medical record review and that medical 
records were available for 98.9% of individuals. Two studies have identified 
major congenital malformations using the Ingenix Research Data Mart (which 
contains medical and pharmacy claims data from United Healthcare affiliated 
health plans) and verified them by medical record abstraction.(8,9) Only one study 
reported on the availability of medical records and that they were available for 
86% of potential major congenital malformation cases.(8) Both studies reported 
only the number of confirmed major congenital malformations and did not 
report the proportion of those identified via the computerized records that could 
be verified, so direct comparison with our study was not possible.  
 
Verification rates in the GPRD, as with the Tennessee Medicaid records, 
appeared to vary by the type of defect recorded. Malformations that were 
compatible with life and required medical intervention or monitoring could be 
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verified relatively easily. For malformations that could be defined as being either 
major or minor depending on anatomical details regarding the malformation 
(e.g. hypospadias, hydronephrosis, syndactyly), as well as for malformations that 
could resolve spontaneously, it proved more difficult to obtain the necessary 
detail. For instance, the six congenital heart defects where there was insufficient 
information to confirm the diagnosis consisted of four ventricular septal defects, 
one patent ductus arteriosus and one case of pulmonary stenosis. We were 
unable to obtain the photocopied records for any of these cases and no 
additional information had been recorded in the free text. It is possible that 
these were less serious, largely asymptomatic defects that did not prompt the GP 
to record additional information in the free text. For six hypospadias cases 
(21.4%) there was insufficient information available to classify as major or minor. 
The EUROCAT guidelines, however, changed in 2005 to include the reporting of 
all cases of hypospadias as a major malformation and therefore the need for 
additional detail to distinguish between major and minor types is no longer an 
issue. 
 
Compared with the photocopied medical records, the free text was less likely to 
provide sufficient information to confirm or refute the presence of a 
malformation. However, if there was evidence that the malformation was 
present, then using the free text enabled the same percentage of malformations 
to be classified as major or minor as with the photocopied medical records. With 
more GP practices scanning patient letters into the free text it is possible that the 
level of detail recorded in the free text has increased over time. 
 
Within this study we chose to request and review full photocopied medical 
records in order to obtain as much information as possible about individuals still 
registered on the database. Previous verification studies of major congenital 
malformations, however, involved using a medical record abstraction 
questionnaire, which has also been found to be successful. Wurst et al.,(3) when 
validating three specific types of congenital heart defect, reported a 94% 
response rate from GPs to the questionnaire and identified a positive predictive 
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value ≥90% for each defect type. Devine et al.(4) created an algorithm to identify 
cases of neural tube defects from the computerized records and then sent 
questionnaires to verify the diagnoses. This study reported a 76.0% response 
rate to the questionnaire, although a small number were sent to GPs where the 
patient concerned had already transferred out of the practice. The overall 
positive predictive value of the algorithm for neural tube defects was 71%, 
ranging from 47% for spina bifida to 83% for encephalocele. Questionnaires are, 
therefore, an additional tool that could be used to verify diagnoses, although 
when attempting to verify a wide range of malformations the photocopied 
medical records have the advantage of not requiring the design of a large 
number of malformation-specific questionnaires. 
 
This study has demonstrated that in a large number of cases, when a 
malformation is identified in the GPRD via the computerized medical records, the 
malformation is likely to exist. There will, however, be a small percentage of 
identified cases (~5%) that need to be excluded due to being incorrectly coded or 
diagnostically ruled out. Therefore, making selected information recorded in the 
free text such as ‘excluded’ or ‘ruled out’ routinely available to researchers 
would be beneficial. For a slightly larger proportion, the malformation identified 
is present but it may be in a minor form. However, for those who are interested 
in aetiology, the inclusion of these cases may well be of value. 
 
6.5 Conclusion 
Postmarketing surveillance programmes are essential to monitor drug safety in 
pregnancy, and require a data source that can reliably capture cases of 
congenital malformations. This study has demonstrated the GPRD can be used to 
ascertain a wide range of congenital malformations. Photocopied medical 
records and to a lesser extent free text have proven valuable sources in carrying 
out verification of malformations identified through the computerized records. 
For more severe malformations and those that are easily externally visible, the 
computerized records were found to be reliable; verification is, however, still 
recommended, especially for those malformations that can occur with different 
 97 
levels of severity. Further work might assess the accuracy and completeness of 
the computerized GPRD malformation codes in a different study population and 
in relation to terminations of pregnancy. 
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7.1 Introduction 
Prescription medications are commonly used by women of childbearing age.(1,2) 
With an estimated 30–50% of pregnancies being unplanned(3,4) and some 
medical conditions (e.g. epilepsy and depression) making it inadvisable to stop 
treatment, there is the potential for women to be exposed to medications during 
the first trimester of pregnancy, which is the critical time period for organ and 
tissue development. Usually pregnant women are excluded from clinical trial 
programmes,(5) and consequently the safety of medicine use during pregnancy 
and its impact on the risk of congenital malformations cannot be fully assessed 
until the drug has been marketed. 
 
Pregnancy registries have been used commonly over the past 2 decades to 
monitor the safety of a new product on the market. Registries aim to detect any 
substantial increase in the risk of major congenital malformations (MCMs), which 
are generally defined as those that are life threatening, require major surgery or 
result in the child having a considerable disability.(6) Pregnancy registries require 
primary data collection, which can be time consuming and costly. Given the 
recent increase in electronic capture of healthcare data for administrative, audit 
and research purposes, in some circumstances data obtained during routine 
clinical practice might be able to address the same questions as those explored 
using pregnancy registries. 
 
The UK General Practice Research Database (GPRD) has been identified as a 
potential data source for the postmarketing surveillance of drug exposure during 
pregnancy.(7) Methods have been developed to identify pregnancies on the 
database(8-10) and to link the mothers’ medical records with those of the 
offspring.(11) Congenital malformations remain the primary outcome of interest 
following drug exposure during pregnancy and studies have begun to verify the 
GPRD (Read/OXMIS) coding system with respect to the identification of some 
specific defect types (cardiac defects(12) and neural tube defects(13)). 
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This study aimed to examine further the potential of the GPRD to serve as a 
pregnancy registry. Given the presence of a number of pregnancy registries 
monitoring antiepileptic drug (AED) use, this study aimed to replicate their 
findings concerning the risk of all MCMs by AED therapy type, and focused the 
comparison on those reported by the UK Epilepsy and Pregnancy Register.(14) The 
UK Epilepsy and Pregnancy Register and the GPRD capture similar geographic 
populations and in both the information on outcome of pregnancy is primarily 
from the general practitioner (GP), which facilitates a comparison of results. This 
study also assessed the utility of the GPRD to identify a known teratogenic 
association, namely the association between first-trimester exposure to 
valproate and the risk of spina bifida.(15,16) Replication of this known teratogenic 
association has also formed part of a validation study by the European network 
of population-based registers for the epidemiological surveillance of congenital 
anomalies (EUROCAT) to assess the validity of using EUROCAT data to detect 
AED-associated risks of specific malformations.(17)  
 
7.2 Methods 
7.2.1 Data sources 
The GPRD is the world’s largest computerized database of anonymised, 
longitudinal medical records from primary care.(18) The GPRD contains over 
55 million person-years of data and currently captures approximately 4 million 
active patients (approximately 7% of the UK population) registered with 
approximately 500 practices within the UK.(19) Virtually all prescriptions, non-
drug interventions and referrals issued by GPs are recorded in the database, as 
are medical diagnoses, including pregnancy. 
 
The UK Epilepsy and Pregnancy Register is a prospective, observational, 
registration and follow-up study.(14) Women can either enrol directly into the UK 
register themselves or they can be enrolled by their healthcare professional (GP, 
epilepsy specialist, neurologist, etc.). Information on AED exposure and 
demographic variables are collected from the referring source before the 
pregnancy outcome is known. Information on pregnancy outcome and the 
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presence of an MCM is collected approximately 3 months after the estimated 
date of delivery via a GP questionnaire. Pregnancies can be reported to the UK 
register retrospectively, after the pregnancy outcome is known, but these are 
excluded from the standard prevalence estimates to avoid selection bias towards 
more severe outcomes. 
 
7.2.2 General Practice Research Database maternal study population 
The GPRD study followed a retrospective cohort design, and women were 
eligible for inclusion if they were, or had been, permanently registered at a GP 
practice considered by the GPRD division at the Medicines and Healthcare 
products Regulatory Agency (MHRA) to be contributing data up to standard for 
the purposes of research. The number of eligible pregnancies and MCMs 
reported in this paper are a subgroup of those reported in an earlier publication 
by Charlton et al.(20) More stringent inclusion criteria for epilepsy have been used 
in the study presented here owing to the need to ensure that the GPRD study 
population was as comparable as possible to those enrolling in the UK Epilepsy 
and Pregnancy Register. Sensitivity analyses were carried out to assess the 
impact on risk estimates of using more stringent inclusion criteria. 
 
In the current study, women were identified as having epilepsy if they had any of 
the following within their medical record: 
 at least two epilepsy diagnosis codes; 
 one epilepsy diagnosis code and at least one AED prescription;5 
 at least two seizure codes (excluding febrile or neonatal seizures) and at least 
  one AED prescription; 
 one epilepsy code and at least two seizure codes (excluding febrile or neonatal  
   seizures). 
 
                                                             
5
 AEDs included acetazolamide, beclamide, carbamazepine, clobazam, clonazepam,  
  ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital,  
  phenytoin, pregabalin, tiagabine, topiramate, valproate, vigabatrin. 
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Of those identified with epilepsy, women with a record relating to a pregnancy 
outcome between 1 January 1990 and 31 December 2006 were identified.  
 
7.2.3 Identifying pregnancy outcomes 
For live- and stillbirths (≥24 weeks’ gestation) the pregnancy outcome date was 
considered to be the date of the first record of a pregnancy outcome when no 
additional records were identified in the preceding 90 days. For terminations of 
pregnancy, the date of the termination was taken as the last recorded 
termination of pregnancy code, within a 6-week window, as earlier termination 
of pregnancy codes commonly related to requests and referrals for an elective 
termination rather than the termination itself. Pregnancy outcomes specifically 
stating that they were a spontaneous abortion or miscarriage were excluded as 
they are beyond the scope of a pregnancy registry because of the likelihood of 
inconsistent identification of defects. Women could contribute more than one 
pregnancy outcome to the study and each unique pregnancy outcome was 
considered separately. 
 
Pregnancies were excluded from the cohort if the woman was not aged 14–
49 years at the date of the pregnancy outcome and if she did not have any codes 
indicating a pregnancy (e.g. last menstrual period (LMP), pregnant, positive 
pregnancy test, antenatal care, etc.) in the 280 days before the pregnancy 
outcome date. Women were required to be continuously enrolled in the GPRD 
for the 4 months before the estimated LMP date and throughout the pregnancy 
to allow reliable assessment of AED exposure. Further pregnancies were 
excluded if the evidence of epilepsy was not recorded before the first medical 
record indicative of a pregnancy. 
 
7.2.4 Linking mother-baby pairs 
The offspring of women meeting all inclusion criteria described above were 
identified where possible (based on having the same family and GP practice 
numbers, and the child’s year and month of birth being equal to the mother’s 
year and month of delivery). To enable comparison with the UK register, which 
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collects outcome data approximately 3 months after the expected delivery 
date,(14) infants of mother-baby pairs were required to be registered in the GPRD 
at 3 months of age or to have been registered and died before 3 months of age. 
 
Major congenital malformations (MCMs) 
7.2.5 Live births 
Medical codes relating to any type of congenital malformation were identified 
using a list of search terms that was created based on the conditions listed in the 
‘congenital anomalies’ chapter of the International Classification of Diseases 9th 
Edition (ICD-9 codes 740–759). Children of women in the cohort who had ≥1 of 
these codes or relevant codes within their hierarchical vicinity were identified 
within the GPRD. 
 
As pregnancy registries are primarily concerned with major malformations, the 
malformations identified were categorized as major or minor. To ensure 
consistency in terms of classification, malformations were categorized according 
to the classification used by EUROCAT. The same classification had been used by 
the UK Epilepsy and Pregnancy Register.(14) Minor defects and malformations 
associated with prematurity, when isolated, are excluded from EUROCAT 
reports. There is also a small number of malformations (e.g. hypospadias, 
hydronephrosis, talipes, syndactyly) that are only classified as major if certain 
criteria are met.(21,22) All congenital malformation codes identified within the 
cohort were reviewed independently by two of the authors. 
 
Malformations identified via the computerized records were confirmed or 
refuted, for those still registered with the practice, by scrutinizing a photocopy of 
the child’s anonymised full medical record, enabling access to all referral letters, 
letters from specialists, hospital discharge reports, etc. For children who had 
transferred out of the practice and for those where the GP did not return 
photocopied records, information recorded in the free-text fields of the patients’ 
entire medical record was obtained and reviewed. Each time a GP records a 
medical code within the GPRD they have the opportunity to record any 
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additional information in the free-text field. This may include a more detailed 
description of symptoms, test results or information relating to diagnostic 
procedures and surgery. All information in the photocopied records and free text 
was anonymised by the MHRA before being returned to the investigators. The 
analyses in the remainder of this study include all confirmed malformations that 
were classified as major and all confirmed malformations where there was 
insufficient information to classify them as minor. For the purpose of this study, 
chromosomal defects, congenital malformations known to be of genetic origin 
and malformations where there was clear evidence that the malformation was 
not drug-induced (e.g. hydrocephalus that was secondary to an intraventricular 
haemorrhage) were excluded. 
 
7.2.6 Terminations, stillbirths and neonatal deaths 
To identify terminations of pregnancy that followed an MCM diagnosis, the free-
text comments recorded in the women’s electronic medical record during the 
2 months before and 4 months after the termination date were obtained. This 
was because these comments were likely, in some cases, to contain additional 
information relating to antenatal scans, diagnostic tests and malformation 
diagnoses. For terminations where the free text did contain information relating 
to an MCM, this was taken to be sufficient evidence and no further supporting 
evidence was required. For pregnancies ending in a stillbirth or a neonatal death, 
free text was obtained for the 2 months before and 6 months after the event. 
This extended time period was chosen to allow any post-mortem results to be 
reported back to the GP. 
 
7.2.7 First-trimester exposure 
To identify the first trimester (first 13 weeks following the LMP), the start date of 
a pregnancy (LMP) for a live birth was assumed to be 280 days before the 
pregnancy outcome date unless there was a record in the woman’s medical file 
indicating that the delivery was pre- or post-mature, in which case the assumed 
LMP date was adjusted accordingly. 
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Prescriptions for AEDs, masked to outcome status, were identified and used to 
establish AED exposure status. Prescriptions were mapped based on the 
assumption that one prescription could not start until the previous one had 
finished unless it was being taken as polytherapy or there was clear evidence of 
drug switching. Where there was evidence of drug switching (i.e. where there 
were continuous prescriptions for a new drug treatment and no more 
prescriptions for the original drug), the first drug was deemed to have been 
discontinued on the date the second one was prescribed. Based on these 
assumptions, exposure status of study participants was determined for each AED 
on each day and women were subsequently classified as having been exposed in 
the first trimester to specific AEDs as well as whether the exposure was mono- or 
polytherapy. 
 
7.2.8 Terminations of pregnancy 
For terminations of pregnancy, gestational age and first-trimester exposure to 
AEDs was ascertained, for MCM cases, by the manual independent review of the 
patient’s electronic prescription records by two of the authors (RC, CdV), masked 
to the type of MCM and the pregnancy start and end dates. 
 
7.2.9 Analyses 
The prevalence of non-chromosomal MCMs meeting the inclusion criteria 
following a range of different AED exposures was calculated. The MCM rate was 
calculated as shown below:  
 
the number of live births with an MCM + the number of pregnancy losses with an MCM 
the total number of live births + the number of pregnancy losses with an MCM 
      
Pregnancy losses (spontaneous abortions, elective terminations and stillbirths) 
without an MCM were excluded from the denominator. This approach is 
commonly taken by pregnancy registries because of the likelihood of 
inconsistent identification of defects across pregnancy losses.(14,23) Multiple births 
were included in the analyses but it was decided a priori that if there was a case 
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of a multiple birth where both/all infants had the same MCM they would only be 
counted once in the numerator and once in the denominator. Relative risks (RRs) 
with 95% confidence intervals (CIs) were calculated using STATA (version 9; 
StataCorp LP, College Station, TX, USA) to compare the risk of a pregnancy 
outcome with an MCM following mono- and polytherapy AED exposure with 
those who had no AED exposure during the first trimester. Comparisons of MCM 
risk were also made for the three most commonly used AEDs. For this, 
carbamazepine was selected as the baseline prevalence as it was the comparator 
chosen in the UK register analyses and it had the largest number of exposures. 
Comparisons with the UK Epilepsy and Pregnancy Register were made with the 
figures that they reported in their publication of December 2006.(14) The above 
analyses were also completed to investigate the association between first-
trimester monotherapy exposure to valproate and spina bifida in the GPRD. 
 
7.3 Results 
7.3.1 Study cohort 
The GPRD study cohort is depicted in Figure 7.1. The cohort consisted of 2019 
live mother-baby pairs, 551 pregnancy terminations, 13 stillbirths and 1 neonatal 
death. Approximately 49% of the mother-baby pair cohort had been exposed to 
≥1 AED during the first trimester of pregnancy. For mother-baby pairs who had 
at least 2 years of data before the start of pregnancy (n = 1497), there was 
evidence that 15.8% had discontinued AED use in the 2 years before becoming 
pregnant. Of those exposed to an AED during the first trimester, 83.2% were 
exposed to monotherapy and 16.8% to polytherapy. The three AEDs most 
frequently prescribed as monotherapy were carbamazepine, valproate and 
lamotrigine (Table 7.1). 
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Figure 7.1 Identifying eligible pregnancies and mother-baby pairs * including twins/triplets 
≥ 1 code relating to a pregnancy outcome 
Unique women  N = 4,096 
Unique pregnancy outcomes  N = 6,284 
 
Not 14-49 years at pregnancy outcome 
Unique pregnancy outcomes  N = 121 
 
Evidence of epilepsy before indicator 
code 
Unique pregnancy outcomes  N = 4,133 
 
 
Pregnancy indicator code in 280 days 
before outcome 
Unique pregnancy outcomes  N = 5,435 
 
 
14-49 years at pregnancy outcome 
Unique pregnancy outcomes  N =  6,163 
 
Diagnosis of epilepsy 
Unique women  N = 29,682 
 
No code relating to a pregnancy 
outcome 
Unique women  N = 25,586 
 
No pregnancy indicator code in 280 
days before outcome 
Unique pregnancy outcomes  N = 728 
 
 
No epilepsy, seizure or convulsion code 
before indicator code 
Unique pregnancy outcomes  N = 1,302 
 
Live births 
Unique women  N = 2,538 
Unique outcomes  N = 3,568 
 
 
Stillbirths / neonatal deaths 
Unique women  N = 14 
Unique outcomes  N = 14 
 
 
Terminations of pregnancy 
Unique women  N = 469 
Unique outcomes  N =  551 
Women permanently registered or transferred 
out of a practice up to research standard 
Unique women  N = 3,134,977 
 
Mother continuously enrolled on GPRD for 4 
months before start of pregnancy and throughout 
Unique pregnancy outcomes  N = 2,394 
 
Unable to link mother and child 
Unique pregnancy outcomes  N = 223 
 
 
 
Child registered at 3 months of age or 
registered and died by 3 months 
Women N = 1,545 
Unique mother-baby pairs  N = 2,019 
 
 
Child registered ≤30 days before or ≤90 
days after mothers outcome date 
Unique mother-baby pairs  N = 2,097* 
 
Able to link mother and child 
Unique pregnancy outcomes  N = 2,171 
 
Live birth pregnancy outcomes 
Unique women  N = 2,538 
Unique pregnancy outcomes N = 3,568 
 
Mother NOT continuously enrolled on GPRD for 4 
months before start of pregnancy and throughout 
Unique pregnancy outcomes  N = 1,174 
Child not registered ≤30 days before or 
≤90 days after mothers outcome date 
Unique pregnancy outcomes  N = 89 
 
 
Child not registered at 3 months of age 
Women  N = 78 
Unique pregnancy outcomes  N = 78 
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Table 7.1 Population characteristics for mother-baby pairs where offspring were 
registered on the General Practice Research Database 
Characteristic Live births 
registered at 
3 months of age
a
 
Live births registered 
at 1 year of ageb 
No. of mother-offspring pairs 2019 1766 
Unique women 1545 1355 
Average age at pregnancy outcome 
[years; mean (SD)]  
30.0 (5.6) 30.1 (5.6) 
Sex of offspring – male (%) 51.2 51.1 
Average number of years infant was 
followed up/present on the 
database (SD)  
5.4 (4.0) 6.1 (3.9) 
First-trimester exposure [n (%)]    994 (49.2) 871 (49.3) 
 monotherapy    818 706 
 polytherapy    164 154 
 drug switching      12   11 
Unexposed  1025 895 
First-trimester monotherapy 
 carbamazepine 355 310 
 valproate 248 221 
 lamotrigine 128   98 
 phenytoin   57   52 
 phenobarbitone   11   11 
 clonazepam     6     4 
 topiramate      5     4 
 gabapentin     4     2 
 ethosuximide     3     3 
 levetiracetam     1     1 
a
 Or registered and died before reaching 3 months of age. 
b
 Or registered and died before reaching 1 year of age. 
 
 
7.3.2 Major congenital malformations 
MCMs by pregnancy outcome 
A total of 82 MCMs in 62 unique live-born individuals were identified and met 
the confirmation criteria. Review of the free text confirmed 14 pregnancies met 
the inclusion criteria and had been terminated following a prenatal MCM 
diagnosis (Table 7.2). No further MCMs were identified following review of the 
free text for either the stillbirths or neonatal deaths. 
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Table 7.2 Number of malformations identified meeting the major congenital 
malformation inclusion criteria 
Malformation No. of malformations 
(live births) 
No. of malformations  
(terminations) 
Neural tube defect 
Hydrocephalus 2 1 
Spina bifida 1 6 
Anencephaly 0 2 
Cardiac  2a 
Atrial septal defect 4 0 
Ostium secundum atrial septal defect 2 0 
Coarctation of aorta 1 0 
Patent ductus arteriosus 1 0 
Pulmonary stenosis 3 0 
Pulmonary artery atresia 1 0 
Tetralogy of Fallot 3 0 
Ventricular septal defect 10 0 
Transposition of great arteries 0 1 
Facial cleft 
Cleft palate 3 0 
Cleft lip and palate 2 0 
Hypospadias/genitourinary tract 
Absence of kidney 1 0 
Atrophy of kidney 1 0 
Hydronephrosis 5 0 
Hypospadias 11 0 
Cystic kidney disease 1 0 
Renal tract disorder 0 1 
Gastrointestinal tract defects 
Hirschsprung’s disease 1 0 
Imperforate anus 2 0 
Tracheo-oesophageal fistula 1 0 
Other 
Congenital cataract 1 0 
Foetal valproate syndrome 4 0 
Hip dislocation/dysplasia 3 0 
Limb reduction 4 0 
Talipes equinovarus 4 0 
Talipes unspecified 1 0 
Polydactyly 3 0 
Syndactyly 2 0 
Multiple abnormalities 0 1 
Reference to ‘congenital anomaly’, i.e. 
club hand, club foot, syndactyly and 
limb defect”? See also Table 7.3  
4 0 
a
 Unable to determine exact malformation type but given that they resulted in an induced  
  pregnancy termination they have been assumed to be major. 
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By infant follow-up 
Of the 82 confirmed MCMs, 53 (64.6%) had been recorded in the GPRD by 
3 months of age and 71 (86.6%) by 1 year of age; a breakdown is shown in Table 
7.3. Given that <65% of confirmed MCMs had been recorded during the first 
3 months of life, it was decided to calculate the prevalence of MCMs at 1 year of 
age. The analysis cohort therefore included only those infants still present in the 
GPRD at age 1 year, those who had registered and died by 1 year of age and 
those pregnancy losses with a non-chromosomal MCM. Of the 2019 mother-
baby pairs within our initial cohort, 1766 (87.5%) met these criteria and, 
including terminations, there were 62 unique pregnancy outcomes with an 
MCM. The characteristics of mother-baby pairs still present in the GPRD at 1 year 
of age were not found to differ substantially from those who were still present at 
3 months of age (Table 7.1). 
 
7.3.3 Prevalence of major congenital malformations 
Type of antiepileptic drug therapy 
Table 7.4 shows the prevalence of MCMs diagnosed by 1 year of age following 
different types of first-trimester AED exposure. An increased risk of an MCM was 
observed in the GPRD following first-trimester polytherapy exposure when 
compared with women having no AED exposure. The point estimates (absolute 
risks) for each exposure category were similar for the GPRD and the UK register; 
however, in the GPRD, the increased risk following polytherapy compared with 
monotherapy did not reach statistical significance (RR 1.73; p = 0.10 compared 
with RR 1.63; p = 0.01).  
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Table 7.3 The age by which malformations in live-born infants were recorded in the 
General Practice Research Database 
Malformation Number of 
live births 
with MCMs  
 
Recorded by 
3 months 
Recorded 
after 
3 months / 
before 1 year 
Recorded 
after 1 year 
Neural tube defect 
Hydrocephalus 2 0 1 1 
Spina bifida 1 1 0 0 
Cardiac 
Atrial septal defect 4 3 0 1 
Ostium secundum atrial 
septal defect 
2 2 0 0 
Coarctation of aorta 1 0 1 0 
Patent ductus arteriosus 1 1 0 0 
Pulmonary stenosis 3 2 0 1 
Pulmonary artery atresia 1 1 0 0 
Tetralogy of Fallot 3 3 0 0 
Ventricular septal defect 10 6 4 0 
Facial cleft 
Cleft palate 3 3 0 0 
Cleft lip and palate 2 2 0 0 
Hypospadias/Genitourinary tract 
Absence of kidney 1 0 0 1 
Atrophy of kidney 1 0 1 0 
Hydronephrosis 5 5 0 0 
Hypospadias 11 8 1 2 
Cystic kidney disease 1 0 0 1 
Gastrointestinal tract defects 
Hirschsprung’s disease 1 0 0 1 
Imperforate anus 2 2 0 0 
Tracheo-oesophageal 
fistula 
1 1 0 0 
Other 
Congenital cataract 1 0 1 0 
Foetal valproate syndrome 4 1 1 2 
Hip dislocation/dysplasia 3 3 0 0 
Limb reduction 4 1 3 0 
Talipes equinovarus 4 2 1 1 
Talipes unspecified 1 1 0 0 
Polydactyly 3 1 2 0 
Syndactyly 2 1 1 0 
Reference to ‘congenital 
anomaly’ i.e. club hand, 
club foot, syndactyly and 
limb defect  
4 3 1 0 
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Table 7.4 Prevalence of major congenital malformations (MCMs) following different types of first-trimester antiepileptic drug exposure 
 
 General Practice Research Database UK Epilepsy and Pregnancy Register 
Exposure type No. of exposures Unique offspring 
with MCMsa 
[n (%)] 
Relative risk  
(95% CI)  
No. of exposures Unique offspring 
with MCMsb 
[n (%)] 
Unadjusted odds ratio 
(95% CI) 
Unexposed 902 22 (2.4) 1 227 8 (3.5) 1 
Monotherapy 711 29 (4.1) 1.67 (0.97, 2.89); p = 0.060 2468 91 (3.7) 1.05 (0.50, 2.19); p = 0.90 
Polytherapy 156 11 (7.1) 2.89 (1.43, 5.84); p = 0.005 718 43 (6.0) 1.71 (0.79, 3.69); p = 0.17 
a
 Recorded in child’s electronic medical record by 1 year of age. 
b
 Outcome data collected approximately 3 months after expected delivery date. 
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7.3.4 Monotherapy exposures 
Table 7.5 shows the prevalence of MCMs for the three most commonly 
prescribed monotherapy exposures. The GPRD observed a higher carbamazepine 
MCM prevalence than was found in the UK register, which, surprisingly, found a 
lower prevalence of MCMs in pregnancies exposed to carbamazepine than in 
unexposed pregnancies. As can be seen from Table 7.5, this had implications for 
the RR estimates of exposure when carbamazepine was used as the baseline 
prevalence. Bearing in mind the known issues with selection bias to pregnancy 
registers, we considered the possibility that for the pregnancy register, 
carbamazepine may have been an inappropriate reference group and it might 
have been more appropriate to compare all exposures with the unexposed 
population. Owing to the lower carbamazepine MCM prevalence, we therefore 
calculated the RR estimates both for the GPRD and the UK register, with the 
unexposed populations as the baseline prevalence (Table 7.5). As a result, risk 
estimates for carbamazepine and lamotrigine were in the opposite direction in 
the GPRD compared with the UK register, and the point estimate for valproate 
was higher in the GPRD than in the UK register, although, as in the register, it did 
not reach statistical significance (RR 2.00; 95% CI 0.99, 4.07; p = 0.05).  
 
7.3.5 Valproate and spina bifida  
The UK register did not report on the rate of spina bifida among monotherapy 
valproate-exposed pregnancies. It did, however, publish the rate of all neural 
tube defects following monotherapy valproate exposures, and this was 
estimated at 1.0% compared with 2.2% in the GPRD. Further analysis in the GPRD 
identified seven cases of spina bifida; one was a live birth and six were 
terminations of pregnancy. Of these, during the first trimester, four cases were 
exposed to valproate in monotherapy, one was exposed to other AEDs in 
polytherapy and two were unexposed to any AEDs. The prevalence of spina 
bifida in valproate monotherapy-exposed pregnancies (resulting in a live birth, 
stillbirth or termination of pregnancy) was 1.78% (95% CI 0.05, 3.50) compared 
with 0.22% (95% CI 0.00, 0.53) for pregnancies with no first-trimester AED 
exposure. The prevalence of spina bifida was significantly higher in the valproate- 
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Table 7.5 Prevalence of major congenital malformations (MCMs) following different monotherapy first-trimester antiepileptic drug exposures with 
carbamazepine as the reference category and then with the unexposed as the reference category 
 
                                General Practice Research Database UK Epilepsy and Pregnancy Register 
Monotherapy 
exposure 
Number of 
exposures (%) 
Unique offspring 
with MCMsa 
[n (%)]  
Relative risk  
(95% CI)  
Number of 
exposures (%) 
Unique offspring 
with MCMsb 
[n (%)]  
Unadjusted odds ratio  
(95% CI)  
Carbamazepine  311 (49.1) 13 (4.2) Reference 900 (39.8) 20 (2.2) Reference 
Lamotrigine 98 (15.5) 3 (3.1) 0.73 (0.21, 2.52); p = 0.77 647 (28.6) 21 (3.2) 1.44 (0.77, 2.67); p = 0.25 
Valproate 225 (35.5) 11 (4.9) 1.17 (0.53, 2.56); p = 0.70 715 (31.6) 44 (6.2) 2.78 (1.62, 4.76); p<0.001 
Unexposed  902 22 (2.4) Reference 227 8 (3.5) Referencec 
Carbamazepine 311 13 (4.2) 1.71 (0.87, 3.36); p = 0.11 900 20 (2.2) 0.63 (0.28, 1.41); p = 0.26 
Lamotrigine 98 3 (3.1) 1.26 (0.38, 4.17); p = 0.73 647 21 (3.2) 0.92 (0.41, 2.05 ; p = 0.84 
Valproate 225 11 (4.9) 2.00 (0.99, 4.07); p = 0.05 715 44 (6.2) 1.75 (0.83, 3.65); p = 0.13 
a
 Recorded in child’s electronic medical record by 1 year of age. 
b
 Outcome data collected approximately 3 months after expected delivery date. 
c
 Calculated by the authors and not reported by the UK Epilepsy and Pregnancy Register. 
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exposed group compared with those unexposed to AEDs (RR 8.02; 95% CI 1.5, 
43.5). 
 
7.4 Discussion 
In this study we were able to identify a known teratogenic association in the 
GPRD, suggesting there may be instances where the GPRD can be used for the 
evaluation of drug safety in pregnancy. Differences were found, however, when 
comparing overall MCM rates for AEDs in the GPRD with UK register data. Below 
we discuss some of the key findings along with strengths and limitations of using 
the GPRD as a tool for postmarketing teratogen surveillance. 
 
7.4.1 Sample size 
The relatively small number of AED exposures in the GPRD was a limitation that 
resulted in wide confidence intervals around many of the MCM prevalence 
estimates. It was known from the outset that the number of first-trimester AED 
exposures in the GPRD was likely to be small, given the low prevalence of 
epilepsy and the fact that the database captures only about 7% of the UK 
population. The GPRD is therefore likely to be better suited to more prevalent 
conditions and the identification of exposures that result in a substantial increase 
in risk. However, the AED drug class was selected for this study in view of the 
large amount of comparator information already available from AED pregnancy 
registries and, more specifically, the presence of the UK register. 
 
7.4.2 Cohort identification and disease status 
Not all women with epilepsy will be recorded explicitly as such. Instead, some 
women with epilepsy will only have records of seizures or convulsions in the 
GPRD. This results from the possibility that an epilepsy diagnosis may have been 
made in a hospital setting and not actually recorded within the woman’s 
electronic medical record. GPs are not required to, and do not, record the 
indication for prescribing with repeat prescriptions. For the purposes of this 
study, we wanted to ensure we captured all epilepsy cases but excluded women 
without epilepsy and women who received AEDs for indications other than 
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epilepsy (e.g. trigeminal neuralgia). Therefore, for women to be taken as having 
epilepsy, they were required to have either ≥2 epilepsy diagnosis codes (without 
the need for supporting evidence) or a single epilepsy code or ≥2 seizure or 
convulsion codes (plus additional supporting evidence within their medical 
record). 
 
It is possible that these inclusion criteria may still have resulted in the inclusion 
of a small number of women in the GPRD cohort who did not actually have 
epilepsy and therefore would not have been eligible for inclusion in the UK 
Epilepsy and Pregnancy Register. These women are likely to fall into the ‘AED 
unexposed’ category and therefore this may, in part, explain the different 
proportions in the exposure categories between the two data sources. An 
alternative or additional explanation for some of the difference in the proportion 
of exposed versus unexposed pregnancies could be that women with epilepsy 
who are not taking AEDs, or who have discontinued using AEDs in preparation for 
their pregnancy, are less likely to choose to enroll and be captured in a 
pregnancy register. Within the GPRD it was found that 15.8% of those who had 
ever received an AED prescription, had discontinued AED therapy during the 
2 years before becoming pregnant. A number of sensitivity analyses were carried 
out to assess the effect of different epilepsy inclusion criteria within the GPRD 
cohort but these were found not to materially alter the risk estimates. 
 
7.4.3 Outcome assessment 
It was possible to identify and verify a wide range of congenital malformations in 
the GPRD. The ability to identify pregnancies in the GPRD with an MCM that 
resulted in a termination of pregnancy was critical in the identification of the 
teratogenic association between first-trimester exposure to valproate and an 
increased risk of a pregnancy outcome with spina bifida. The severe nature of 
spina bifida and the fact it is often diagnosed prenatally meant that without the 
terminated pregnancies and supporting free text this association would not have 
been identified. The inclusion of pregnancy terminations is important for the 
identification of any severe or life-threatening malformation diagnosed 
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prenatally. Registries have the benefit of a review of MCM cases by an 
experienced teratologist, but a potential strength of using the GPRD is the ability 
to capture more completely than registries those pregnancies that do not result 
in a live birth. 
 
7.4.4 Exposure assessment 
The GPRD has the advantage that prescription data is recorded prospectively and 
independently of the pregnancy outcome. The level of certainty with which it is 
possible to determine timing of exposure in the GPRD is limited by the level of 
precision with which it is possible to estimate the exact LMP date and 
subsequently the first trimester. The GPRD is therefore more appropriate for 
medicines used to treat chronic, rather than episodic, conditions where exposure 
is likely to be continuous. Exposure assessment in the GPRD is, however, purely 
based on the issue of prescriptions and there is no way of establishing if and 
when the medicine has been taken. Exposure information in the GPRD is also 
limited to medicines available for use in the UK that require a prescription; it 
does not capture over-the-counter medicines. 
 
Both the GPRD and the UK register reported carbamazepine, valproate and 
lamotrigine as the most commonly used AED monotherapies during the first 
trimester of pregnancy. The UK register observed a higher proportional 
representation of lamotrigine exposures than the GPRD. Given that lamotrigine 
was not launched in the UK until 1992 and would have taken time to penetrate 
the market, this difference could be the result of the different time periods of 
data collection, with the GPRD study including pregnancy outcomes from 1990 
and the UK register starting in December 1996. Further analyses restricting the 
GPRD data to the same time period as the UK register, however, still found the 
register to have a higher proportion of lamotrigine use. This difference could 
therefore be an example of selection bias within the UK register, with women 
and healthcare professionals being more likely to report lamotrigine exposures 
as it is a relatively new drug on the market. 
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7.4.5 Differences in risk assessment 
The UK register reported comparative risk analyses between AED monotherapy-
exposure groups using carbamazepine as the reference exposure category. 
However, the prevalence of MCMs associated with carbamazepine use in the UK 
register was lower than that observed for the unexposed group and lower than 
corresponding risk estimates in the GPRD. This, in great part, underlies the 
differences in comparative results between the UK Register and the GPRD, and 
illustrates the problem of choosing an appropriate comparator group for these 
studies of drug safety in pregnancy. Indeed, it highlights the issue of whether a 
comparator group should be chosen for pregnancy registry studies monitoring 
for a signal of major teratogenicity where the effects, if present, are likely to be 
so great they usually will need no comparison groups or consideration of 
confounding variables.(24,25)  
 
Irrespective of any comparator group, both data sources reported a lower 
prevalence of MCMs following first-trimester exposure to valproate than has 
been reported in a number of studies outside the UK.(26-30) The reason for this is 
unclear and further investigation would be required to determine whether it is 
related to differences in recording, differences in the use of valproate in the UK, 
differences in the use of concomitant folic acid, or other factors. 
 
7.4.6 Follow-up 
Outcome information is often requested by pregnancy registries close to the 
expected date of delivery (often within the first 3 months of life). Within the 
GPRD, fewer than 65% of MCMs were recorded by 3 months of age, which may 
demonstrate a need to follow infants for longer in the GPRD than in registries in 
order to obtain representative outcome data. Loss to follow-up is an issue with 
all prospective observational studies. Although in the UK register loss to follow-
up was only 8.1%, in some registries it can be as high as 27%.(23) Within the GPRD 
there is the potential for infant follow-up to extend beyond the period 
immediately after birth, with the mean length of infant follow-up within this 
study cohort being 6.1 years (SD 3.9).  
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7.4.7 Confounders 
In order to encourage enrolment, and given that pregnancy registries are 
designed to identify major teratogens, the amount of information requested in 
terms of potential confounding factors is often limited. Although not evaluated 
in this study, information is available within the GPRD on potential confounders 
such as age, smoking status, alcohol status, body mass index, co-morbidity and 
other prescription medications; however, further work is required to look at the 
completeness, accuracy and reliability of these variables. 
 
7.4.8 Comparison of data sources 
The UK Epilepsy and Pregnancy Register was set up with an entirely different aim 
than that of the GPRD. Consequently, the methods of data collection used by 
computerized medical record databases and pregnancy registries do differ and 
these differences have implications for the type of information available and the 
extent to which direct comparisons can be made. Pregnancy registries often rely 
on voluntary enrolment and therefore may not always capture a truly 
representative sample of those either with the disease of interest or using the 
medication of interest. Whilst such selection bias is an issue, the indication for 
prescribing is usually unambiguous and typically pregnancy registries have 
detailed information regarding birth defects identified at birth. In contrast, whilst 
in the GPRD selection bias is negligible or absent, the indication for prescribing is 
implicit rather than explicit because it is influenced from the presence of 
diagnostic and symptom records and the absence of alternative explanations. In 
addition, to obtain detailed information regarding malformations identified, 
exploring the electronic records does not suffice. Instead, free text or hospital 
letters need to be consulted.(20)  
 
7.5 Conclusions 
Postmarketing surveillance of pregnancy outcomes to identify potential 
teratogens is essential because of the lack of evidence available when a new 
product is first marketed regarding its safety when used during pregnancy. The 
GPRD has proven useful in the identification of malformations and of a major 
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teratogenic association. The GPRD does, however, identify fewer exposed 
pregnancies than a pregnancy registry, especially for less prevalent conditions; 
therefore, in many circumstances pregnancy registries are likely to remain the 
optimum method of surveillance. Given limitations in sample size, the GPRD is 
going to be most capable of identifying major risk factors rather than those that 
result in a relatively small increase in risk. The GPRD may also be better suited to 
monitoring medicines used to treat more prevalent conditions, such as 
depression, or medicines that have been on the market for a long time for which 
no registry has been set up. 
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8.1 Introduction  
Post marketing surveillance for the detection of potential teratogens and other 
harmful effects is essential given the limited amount of information available 
when a new medicine is introduced on the market. It has been reported that 
approximately 37% of clinically recognised pregnancies end in a spontaneous 
pregnancy loss or an induced termination,(1) emphasising the need for these 
types of pregnancy outcome to be monitored in addition to live- and still- births 
when evaluating the safety of a medicine used during pregnancy. Over the past 
two decades there have been major advances in prenatal screening(2, 3) and now 
it is increasingly likely that some severe congenital malformations, such as neural 
tube defects, will be diagnosed prenatally. Women may subsequently opt to 
have their pregnancy terminated. The fact that teratogens are likely to increase 
the risk of selected defects, rather than all defects,(4) means it is possible that if 
the selected defect type can be diagnosed via prenatal screening the increase in 
risk may go undetected, if terminations of pregnancy are not captured in 
postmarketing safety evaluations. The optimum data sources for post marketing 
teratogen surveillance will therefore be those that can capture all types of 
pregnancy outcome and distinguish between induced pregnancy terminations 
that were carried out for medical and non-medical reasons. 
 
The General Practice Research Database (GPRD) has been identified as a 
potential source for monitoring pregnancies and pregnancy outcomes.(5-8) The 
importance of including terminations of pregnancy when evaluating pregnancy 
outcomes in the GPRD has been demonstrated for neural tube defects in 
general(9) and in relation to first trimester exposure to valproate and a pregnancy 
outcome with spina bifida specifically.(10) Hardy et al.(8) and Devine et al.(7) have 
both reported on the generation of an algorithm to identify different types of 
pregnancy outcome within the GPRD. In this chapter we focus on pregnancy loss 
and describe the development of an algorithm to categorise pregnancy losses 
into those that were spontaneous and those that were induced and for those 
that were induced, whether or not they were carried out following prenatal 
diagnosis of a congenital malformation (including chromosomal abnormalities). 
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8.2 Methods 
8.2.1 Data source 
The GPRD is the world’s largest computerised database of anonymised, 
longitudinal medical records from primary care.(11) At present it contains over 57 
million person years of data and is actively collecting data on approximately 4 
million patients (~7% of the UK population) registered with around 500 GP 
practices within the UK.(12) The GPRD consists largely of coded data entered onto 
a computer system by GPs as part of the clinical management of patients. There 
are over 3,500 different medical codes relating to pregnancy that a GP can enter 
into a patient’s record on the database. In addition to pregnancy related data the 
GPRD also captures other medical diagnoses, prescriptions, referrals and 
consultations. As well as recording medical codes, GPs have the option of 
recording additional, non-coded, information relating to a particular diagnosis in 
the free text field. This free text is not readily available to researchers but can be 
purchased from the database provider separately on a per project basis. 
 
8.2.2 Identification of pregnancy related medical codes 
All medical codes relating to pregnancy, childbirth and termination, including 
those referring to antenatal, neonatal and postnatal care, were identified using a 
list of search terms and then reviewing those in the hierarchical vicinity. Codes 
indicating a negative pregnancy test were excluded. Each code was assigned to 
one of the following categories: delivery (including stillbirths), pregnancy loss 
(including both spontaneous and induced abortions), a postpartum event, a 
preterm delivery, a post-term delivery and any remaining codes that provided 
additional supporting evidence of a pregnancy. Codes were then grouped 
according to whether they provided sufficient evidence of a pregnancy or 
whether additional supporting evidence in the form of another pregnancy 
related code was required.  
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8.2.3 Study population 
The study period ran from 1 January 1992 until 18 February 2009. The study 
population consisted of females with ≥1 code indicating a pregnancy potentially 
ending between January 1992 and their right censor date (date of last data 
collection, date the patient died or left the practice or the date the practice 
stopped contributing data considered by the GPRD group at the Medicines and 
Healthcare products Regulatory Agency to be up-to-standard (UTS) for the 
purposes of research). Pregnancies occurring before a patient’s left censor date 
(latest of registration date or date the practice was first considered to be 
providing data that is UTS) were excluded.   
 
8.2.4 Identification and classification of pregnancy losses 
All pregnancy outcomes were identified in the GPRD and categorised as being a 
delivery (including stillbirths) or a pregnancy loss. For each patient with a medical 
code that required supporting evidence, a check was made to ensure at least one 
additional, different pregnancy related code was present within a specified time 
frame (which was dependent on the category of the code).  
 
For each patient, pregnancy loss events were assessed in ascending date order 
with the last event in a series of 6 weeks being taken as the pregnancy end date. 
This was because earlier codes of pregnancy loss commonly related to requests 
and referrals for a termination rather than the date of the termination itself. As a 
consequence, where two pregnancy loss events occurred in short succession but 
with more than six weeks between the first and last recording, the second 
pregnancy loss was omitted from our analyses.  
 
The start date of the pregnancy was determined, where possible, from the 
following records in order of priority; estimated date of delivery (EDD), EDD 
calculated from record for last menstrual period (LMP), EDD calculated from 
delayed/missed period, default pregnancy length for a pregnancy loss (10 
weeks). There were a number of apparent deliveries (codes included ‘delivery 
details’ and ‘birth details’) that were contradicted by the existence of miscarriage 
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records within days of the coded ‘delivery’. Manual review of a sample of these 
patients’ medical records made it apparent there were instances where GPs 
recorded codes implying a delivery when actually it was a pregnancy loss. Where 
a record for a delivery had a code for a spontaneous or induced pregnancy loss 
within the 42 days before or 21 days after, the delivery record was disregarded.  
 
An algorithm was created to categorise, with varying levels of certainty, a 
pregnancy loss relating to either an ectopic pregnancy, a hydatidiform mole, a 
spontaneous abortion or an induced termination. Where we were unable to 
classify pregnancy losses, the type of loss was classed as unknown. For losses 
categorised as being induced terminations, medical codes and prescriptions were 
scrutinised to determine whether the termination was induced following a 
prenatal diagnosis of a congenital malformation or for non-medical reasons.  
 
8.2.5 Review of free text comments 
To evaluate the reliability of the algorithm, free text comments recorded during 
the two months before a pregnancy loss and four months after were requested 
and reviewed for a sample of 200 pregnancy losses. 
 
8.2.6 Data analysis 
The percentage of identified pregnancies that resulted in a delivery and a 
pregnancy loss was calculated. The number and percentage of pregnancy losses 
that were identified at each stage of the algorithm were then grouped into the 
different types of pregnancy loss. The percentage of identified induced 
terminations with evidence to suggest they were carried out for a foetal medical 
condition was also calculated and compared to national statistics. To increase 
the likelihood that only true pregnancies were included, those pregnancies 
where the female was not 11-50 years of age at the time of the pregnancy 
outcome were excluded from the analyses. Comparisons were made between 
the algorithm end point of a pregnancy loss and the information recorded in the 
free text comments.  
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8.3 Results  
8.3.1 Identification of pregnancy losses 
In total 529,975 pregnancies were identified. Of these, 370,528 (69.9%) resulted 
in a delivery and 159,447 (30.1%) in a pregnancy loss. For deliveries and 
pregnancy losses the mean age at pregnancy outcome was 29.8 years (SD†† = 5.8) 
and 28.8 years (SD = 7.4) respectively. 
 
Figure 8.1 shows the number of pregnancy losses identified at each stage of the 
algorithm. The number and percentage of pregnancy losses that could be 
categorised as being spontaneous, induced and unknown are shown in Table 8.1. 
 
8.3.2 Categorisation of pregnancy losses 
For 82.0% of all pregnancy losses sufficient information was recorded to 
categorise the pregnancy loss as being either spontaneous, ectopic, a 
hydatidiform mole pregnancy or induced. For the remaining 18.0% there was 
insufficient evidence to determine the type of pregnancy loss.  
 
For pregnancy losses recorded as being induced (or assumed induced) 
terminations it was found that medical codes specifically stating the reason for 
the termination were recorded in less than 0.2% of cases. In 62.8% of cases, 
however, there were medical codes providing evidence of a planned/wanted 
pregnancy, an unplanned/unwanted pregnancy or a congenital malformation, 
enabling an assumption to be made as to the reason for the termination.  
 
Of all pregnancy losses categorised as being induced (or assumed induced), 0.1% 
had medical codes specifically stating they were carried out owing to a medical 
indication. In addition, a further 1.7% had medical codes relating to the presence 
of a congenital malformation or providing evidence that it was either a 
planned/wanted pregnancy, allowing the assumption to be made that the 
pregnancy was terminated for medical reasons.  
                                                             
††
 Standard deviation 
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For each set of termination records for a patient 
Ectopic  
N = 5,391
Hydatidiform mole  
N = 564
 Spontaneous abortion  
N = 55,359
Induced termination – medical
N = 77
Induced termination – non medical
N = 1
Induced – assume non medical
N = 19,597
Assume induced – assume non 
medical
N = 14,859
Type unknown – assume medical
N = 1,475
Type and reason unknown
N = 27,280
Induced – assume medical
N = 714
Y
N
Y
Y
N
N
Y Y
N
N
Y
N
Assume induced – assume medical
N = 235
Induced – reason unknown
N = 15,108
Assume induced – reason unknown
N = 5,779
Assumed spontaneous abortion
N = 13,008
Y
Ectopic record exists?
Spontaneous abortion 
record exists?
Hydatidiform record 
exists?
Induced for medical 
reason record exists?
Medical code suggestive 
of a spontaneous abortion 
exists?
N
N
N
N
Unplanned/
unwanted 
pregnancy record 
exists?
Evidence of 
planned pregnancy 
or congenital 
malformation?
Induced termination 
record exists?
Induced for non-medical 
reason exists?
Y
Y
Y
N
Unplanned/unwanted 
pregnancy record exists?
N
Y
Referral for 
termination 
record exists?
Evidence of 
planned pregnancy 
or congenital 
malformation?
Evidence of 
planned pregnancy 
or congenital 
malformation?
Y
N
Key
Medical = carried out for foetal medical 
reasons e.g. a prenatally diagnosed 
congenital malformation
Non-medical = carried out for reasons 
other than a foetal medical condition
Examples of medical codes
Spontaneous abortion e.g. ‘miscarriage’, ‘spontaneous abortion’, complete spontaneous abortion’
Medical code suggestive of spontaneous abortion e.g. ‘missed abortion’, retained products of conception removed’
Induced for medical reasons e.g. ‘termination of pregnancy – medical indication’, ‘therapeutic abortion’
Induced for non-medical reasons e.g. ‘abortion induced – social reasons’
Induced termination e.g. ‘legally induced abortion’, 
Evidence of unplanned or unwanted pregnancy e.g. ‘pregnant – unplanned’, ‘unwanted pregnancy’
Evidence of planned pregnancy e.g. ‘planned pregnancy’, prescriptions for pre-conceptional folic acid, treatment for infertility or prevention of miscarriage
Congenital malformation e.g. a code for a congenital malformation recorded during pregnancy or in the 30 days after the termination date
Y
N
 
Figure 8.1 The number of pregnancy losses identified at each endpoint of the algorithm  
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Table 8.1 Breakdown of the number of different types of pregnancy loss identified   
Type of pregnancy loss                                                     
Number of 
pregnancy 
losses 
Percentage of 
pregnancy 
losses 
Percentage of 
all 
pregnancies 
    N = 159,447 N = 529,975 
Spontaneous 68,367 42.8 12.9 
Of which -        
- specific spontaneous / miscarriage code 55,359 34.6   
- contributory evidence was spontaneous
1 
13,008 8.1   
    
Ectopic 5,391 3.4 1.0 
Hydatidiform mole 564 0.4 0.1 
        
Induced / assumed induced 56,370 35.4 10.6 
       
- for medical reasons
2 
77 <0.1   
- assume for medical reasons
3 
949 0.6   
- for non-medical reasons
4 
1 <0.1   
- assume for non-medical reasons
5 
34,456 21.6   
- reason unknown 20,887 13.2   
        
Unknown 28,755 18.0 5.4 
       
- assume not induced for non-medical reasons
6 
1,475 0.9   
- reason unknown 27,280 17.1   
 
1 
Codes including ‘missed abortion’, ‘retained products of conception removed’ 
2 
Codes including ‘termination of pregnancy – medical indication’, ‘therapeutic abortion’  
3
 Based on evidence of a planned or wanted pregnancy, pre conceptional folic acid prescriptions,   
   a congenital malformation, amniocentesis, treatment for infertility  
4 
Codes including ‘abortion induced – social reasons’ 
5 
Based on evidence of an unwanted or unplanned pregnancy e.g. ‘pregnancy – unwanted’ 
6 
Evidence of a planned pregnancy; type of loss therefore assumed either spontaneous or induced 
  for medical reasons 
 
 
8.3.3 Verification of the algorithm 
Review of the free text comments for 200 pregnancy losses found for 108 
pregnancies the free text provided confirmation of the algorithm endpoint. For a 
further 51 pregnancy losses that the algorithm had categorised as type and/or 
reason unknown, the free text provided additional information enabling the type 
and reason for the pregnancy loss to be determined. Four of these were found to 
be induced for medical reasons. In 7 pregnancies the free text contained 
information that contradicted the type of pregnancy loss derived by the 
algorithm and for the remaining 34 pregnancy losses the free text contained no 
relevant additional information (Table 8.2). 
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   Table 8.2 Comparison of algorithm end points with those derived from review of the free text comments 
 
                                      Type of pregnancy loss based on review of free text comments 
Ty
p
e
 o
f 
p
re
gn
an
cy
 lo
ss
 b
as
e
d
 o
n
 
th
e
 a
lg
o
ri
th
m
 c
at
e
go
ri
sa
ti
o
n
  Spontaneous Induced for 
medical 
reasons 
Induced for 
non-medical 
reasons 
Induced – 
reason 
unknown 
Type and 
reason 
unknown 
Spontaneous 
19    2  2   4 
Induced for 
medical reasons 
 3   2   1 
 
  1 
Induced for non- 
medical reasons 
 1 64 12 10 
Induced – reason 
unknown 
 
1 20 13   6 
Type and reason 
unknown 
 
3 19   8   9 
 
    Summary of algorithm end points 
    Spontaneous = Ectopic + Hydatidiform mole + Spontaneous abortion + Assumed spontaneous abortion 
    Induced for medical reasons = Induced-medical + Induced assume medical + Assumed induced assume medical +  
    Unknown assume medical 
    Induced for non-medical reasons = Induced-non medical + Induced assume non-medical + Assumed induced assume  
    non-medical + Assume induced non-medical 
    Induced – reason unknown = Induced unknown + Assume induced unknown 
Key 
 Algorithm verified using free text 
 
 Free text contradicts algorithm 
 
 Free text provides additional 
information 
 
 No further additional insights gained 
                from free text 
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8.4 Discussion 
In this study we developed an algorithm to identify and classify, with varying 
levels of certainty, pregnancy losses recorded in the GPRD. For 82.0% of 
pregnancy losses there was a sufficient level of detail available to categorise 
them as being either spontaneous or induced, whilst for 18.0% the medical codes 
did not provide sufficient information regularly on the type of pregnancy loss. 
The percentage of pregnancies falling into each of the pregnancy loss categories 
in this study corresponded closely with what has been reported in the literature. 
Of all pregnancies, 12.9% resulted in a spontaneous abortion compared with 
estimates of between 10 and 20% in the literature.(13, 14) It is thought the 
percentage of spontaneous pregnancy losses in the GPRD will be slightly 
underestimated as a proportion of the pregnancies that the algorithm was 
unable to classify are likely to have been spontaneous abortions. In addition 
some early pregnancy losses may never come to the attention of the GP. The 
algorithm classified 1.0% of all pregnancies in the GPRD as being ectopic and 
0.1% as resulting in a hydatidiform mole, both of which correspond with what 
has been reported elsewhere.(15) 
 
It was found that 10.6% of all pregnancies could be categorised as being induced 
(or assumed induced) terminations. Again this percentage will be slightly 
underestimated owing to the proportion of pregnancies we were unable to 
classify with the algorithm developed. Of those classified as induced or assumed 
induced, 0.1% had a medical code specifically stating that the pregnancy was 
terminated for a congenital malformation whilst a further 1.7% had medical 
codes relating to a congenital malformation or the fact the pregnancy was 
planned and/or wanted, implying it was likely to have been terminated for 
medical reasons. In England and Wales in 2010, 1.2% of all induced terminations 
were justified under ground E, “that there was substantial risk that if the child 
were born it would suffer from such physical or mental abnormalities as to be 
seriously handicapped.”(16)  It therefore appears that the algorithm may slightly 
overestimate the proportion of induced terminations carried out following a 
diagnosis of a congenital malformation. Alternatively it is possible that not all 
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terminations carried out due to a congenital malformation are recorded under 
ground E. In 2010, 97.7% of all terminations were justified under ground C, “that 
the continuance of the pregnancy would involve risk, greater than if the 
pregnancy were terminated, of injury to the physical or mental health of the 
pregnant woman.” It is therefore possible some additional terminations owing to 
a congenital malformation may have been recorded in this category. In drug 
safety in pregnancy studies it is critical that all pregnancy outcomes identified as 
having a congenital malformation are true cases of a congenital malformation. 
This study and previous research using the GPRD(10) has demonstrated the added 
value of obtaining free text in order to gain additional information relating to a 
termination of pregnancy and we recommend requesting this free text for those 
terminations of pregnancy that have been identified as potentially being induced 
for a foetal medical condition in order to find further evidence of the prenatal 
diagnosis. 
 
Unlike Devine et al.,(7) who categorised all pregnancy losses, we were unable to 
determine the type of pregnancy loss for 18.0% of pregnancy losses identified. 
Classification of pregnancy losses in the GPRD into those that are spontaneous 
abortions and those that are induced terminations is complicated by the multiple 
and sometimes unspecific medical codes that can be used to record the event in 
the database. In addition pregnancy loss terminology, including the terms 
‘abortion’ and ‘termination’ is used interchangeably to describe both a 
spontaneous and an induced pregnancy loss and this is likely to vary between 
GPs. It is therefore not possible to determine whether the medical code 
‘unspecified abortion’ is referring to a spontaneous or induced pregnancy loss. 
Identification of supporting evidence in relation to a referral for a termination or 
a planned pregnancy is therefore important.  
 
A small proportion of clinically recognised pregnancy losses will not be captured 
in the GPRD. This will consist of some early spontaneous abortions and a small 
number of induced terminations that were not recorded in the database by the 
patient’s GP. In 2010, 96% of induced terminations in England and Wales were 
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funded by the NHS(16) and in the majority of cases the patient will have been 
referred by their GP so the number that will have been missed is expected to be 
small. 
 
Owing to the nature of the data source and incomplete data recording within the 
GPRD assumptions needed to be incorporated into the algorithm and it is 
possible that in some cases these may have resulted in misclassification of 
pregnancy outcomes. Initially folic acid prescriptions in the 90 days before and 
56 days after LMP were taken as evidence of a planned pregnancy, however on 
review there were a number of cases where folic acid was prescribed on the 
same date a woman was requesting a pregnancy termination. An assumption 
was made that these women were being advised to take folic acid in case they 
changed their mind about having a termination. The final algorithm was 
subsequently adjusted to ignore folic acid codes unless it had been prescribed 
before the first pregnancy code (excluding LMP) was recorded. There may also 
be examples where a pregnancy was planned, but for a non-medical reason, the 
woman later changed her mind and decided to opt for a pregnancy termination. 
In the GPRD, only the planned nature of the pregnancy might have been 
recorded as a medical code and as a result this pregnancy will have been 
incorrectly classified as ‘assumed induced for assumed medical reasons’.  
 
The extent to which the free text provided supporting evidence was reassuring. 
Informative free text was available for 166 of the 200 pregnancy losses verified 
and the type of pregnancy loss, determined by the algorithm, was only 
contradicted by the free text in 7 cases. The free text provided additional 
information enabling the categorisation of 51 pregnancy losses where the 
algorithm had categorised them as type and/or reason unknown and this 
included 4 that were induced for medical reasons. The cost of free text, however, 
means it will often not be feasible to request it for all unclassified pregnancy 
outcomes. For specific drug safety in pregnancy studies however, an algorithm 
could be developed to identify free text needing to be reviewed based on a 
search of key words indicative of a type of pregnancy loss (e.g. spontaneous, 
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induced, elective, therapeutic) or a congenital malformation (e.g. anomaly, 
malformation, birth defect, spina bifida, anencephaly, amniocentesis etc.). Whilst 
the algorithm was found to be useful, it is not perfect and for specific drug safety 
in pregnancy evaluations should be supplemented with review of the free text 
comments where possible.  
 
8.5 Conclusion 
The inclusion of pregnancy losses, especially those induced following a prenatal 
diagnosis of a congenital malformation, is important when carrying out 
postmarketing surveillance for potential teratogens. One of the key strengths of 
the GPRD, unlike some other electronic healthcare databases, is the fact that, 
although it is incomplete for early loss, it does capture both spontaneous and 
induced pregnancy losses in addition to deliveries. This study has shown that not 
only can pregnancy losses be identified in the GPRD but for over 80% it is 
possible to categorise the type of pregnancy loss and for induced terminations it 
is possible to identify those that may have been carried out as the result of a 
foetal medical condition. The GPRD may therefore complement other data 
sources and provide additional insight in areas where some data sources and 
methods fall short.  
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Chapter 9 
 
General discussion 
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9.1 Overall discussion of study results 
This thesis aimed to evaluate the utility of the United Kingdom’s General Practice 
Research Database to act as an alternative or complement to pregnancy 
registries. In this chapter I address each of the eight objectives in turn, briefly 
describe how they were met and discuss the study findings and their 
implications. In addition I suggest areas for future research as well as 
summarising some key ongoing developments. Based on all the evidence 
presented in this thesis I then draw final conclusions on the potential of the 
GPRD in the field of drug safety in pregnancy research and the areas where it has 
been demonstrated it can provide a valuable contribution.  
 
Identification of pregnancies in the GPRD 
 The first objective was to identify pregnancies recorded in the GPRD within a 
cohort of women with epilepsy.  
 
Using the algorithm described in Chapters 4 and 6 it was possible to identify 
pregnancies within a cohort of women with epilepsy in the GPRD. Pregnancies 
resulting in a live birth, stillbirth, spontaneous pregnancy loss or induced 
termination were identified and the proportions of pregnancies ending in a 
delivery and pregnancy loss were found to be in line with what has been 
reported in the literature.(1-3) As outlined in Chapter 8, live births should not be 
studied in isolation when carrying out drug safety in pregnancy research and 
therefore the range of pregnancy outcomes captured in the GPRD is a 
considerable strength over some other data sources.  
 
The algorithm used to identify pregnancies in this study has not, however, been 
validated and this is something that could be considered in the future. The paper 
by Devine et al. (2009), reporting on a study to identify pregnancies in the GPRD, 
included two verification exercises to assess the reliability of the number and 
type of pregnancy outcomes identified.(4) These found the reliability of live birth 
identification to be greater than that of pregnancy losses and preterm, post-term 
and multiple birth outcomes. For the algorithm used in this thesis, in addition to 
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verifying the type of pregnancy outcome, it would also be of benefit to evaluate 
the accuracy of LMP dates estimated by the algorithm. This is important as these 
play a significant role in determining the timing of exposure.(5) A verification 
exercise could involve requesting free text comments for a sample of 
pregnancies to evaluate whether the precise date of the woman’s LMP has been 
entered by the GP as free text and whether there are text comments to support 
the estimated date of pregnancy outcome. It is likely the introduction of an 
‘event date’ field in the GPs computer software, in addition to an ‘entry date’ 
field, will have gone some way to reduce LMP dates being incorrectly recorded 
on the date the woman visited the GP rather than the date of the actual event 
but this is something that could also be investigated by review of the free text.  
 
Determining first trimester drug exposure in the GPRD 
 The second objective was to identify, within the cohort of women with a 
diagnosis of epilepsy, those who were exposed to anticonvulsants during the 
first trimester of pregnancy.  
 
Prescriptions issued in the four months before the estimated LMP date and 
throughout pregnancy were identified in the women’s medical records. The 
duration of each prescription was mapped based on quantity and daily dose. This 
was done to ensure women were classified as exposed if they received a 
prescription before pregnancy that contained enough tablets to allow exposure 
to continue during the start of pregnancy. Based on my evaluation of the 
prescribing patterns, where continuous prescribing was identified for most 
mothers, I conclude that for anticonvulsants, prescription episodes reflected 
exposure in practice. 
 
For many medicines, estimating the timing of drug exposure can only be as 
accurate as the estimated timing of the pregnancy start date. When determining 
the pregnancy start date, attempts were made to utilise all information relating 
to gestational age, prematurity, estimated date of delivery and LMP date. The 
level of detail that went into determining pregnancy start dates and mapping 
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prescriptions will have helped to minimise, although not ruled out, exposure 
misclassification within our study cohort. Establishing exposure based on the 
issue of a prescription avoids recall bias, which has the potential to affect the 
findings of studies carried out using data sources that rely on maternal self 
reporting.(6) It does, however, mean it is not possible to obtain information on 
non-compliance and whether the drug was actually taken. It is for these reasons 
that GPRD data may be better suited to evaluating the risk of exposures used to 
treat chronic conditions where discontinuation of exposure is not advised. 
Epilepsy is a good example of such a condition. 
 
Once women with first trimester exposure to anticonvulsants had been 
identified it became apparent that the percentage of women with treated 
epilepsy was considerably lower than expected. Initially we had identified all 
women with a code relating to epilepsy, seizure or convulsion in an attempt to 
capture as many as possible. The rationale behind this was that the epilepsy 
diagnosis could have been made in a hospital and not specifically recorded as a 
medical code by the woman’s GP. The low percentage of anticonvulsant 
exposure, however, confirmed that this search strategy was too broad and that 
the presence of a single code within an individual’s medical record should not be 
taken as a guaranteed diagnosis. The initial cohort was used for the study 
reported in Chapter 6 to allow the recording of as many malformations as 
possible to be evaluated. For the risk assessment study in Chapter 7, the 
inclusion criteria was restricted to ensure the cohort was more in line with those 
enrolled in the UK Epilepsy and Pregnancy Register. For this, supporting evidence 
in the form of multiple seizure or epilepsy codes or prescription records was 
required.  
 
Accurate identification of the population under study is important, particularly in 
risk assessment studies where it is thought the medical condition itself could be 
a risk factor for adverse pregnancy outcomes. The requirement of supporting 
evidence will go some way to reduce misclassification but further verification 
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studies of coding of specific medical conditions recorded in the GPRD are also 
needed. 
 
Linking the mother’s medical record to the child’s record 
 The third objective was to link, for live deliveries identified in objective one, 
the mother’s medical record to that of the child.   
 
For approximately 90% of the live deliveries it was possible to link the mother to 
the child. This was based on them having the same family and GP practice 
numbers, and the child’s year and month of birth being equal to the mother’s 
year and month of delivery. This has implications for statistical power when 
determining whether or not to use the GPRD for evaluations of drug safety in 
pregnancy. However, it will only impact on the risk estimates if women who 
cannot be linked to their child differ systematically in terms of risk factors for 
adverse pregnancy outcomes to those where a link can be made. To my 
knowledge no study has compared the patient characteristics of women who can 
and cannot be linked to their child. For drug utilisation studies all exposed 
women, regardless of a mother-baby link can be included. 
 
Identification and verification of congenital malformations in the GPRD 
 The fourth objective was to identify major congenital malformations in 
offspring of women identified in objective one. Objective five then set out to 
verify these malformations using either full photocopied medical records or 
free text comments.  
 
It was possible to identify a wide range of congenital malformations in the GPRD. 
For malformations identified within the medical record of the child it was 
possible to verify 85.1% of cases using either the photocopied medical records or 
free text. Of those, 78.1% had sufficient evidence to be categorised as major 
congenital malformations, 15.0% were found to be minor anomalies and for 
6.9% there was insufficient information to determine the severity of the 
malformation. When it came to determining the presence of a congenital 
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malformation, the photocopied medical records were found to be more 
informative than the free text. Where there was sufficient information to verify 
the presence of a malformation, however, the percentages that could be 
categorised as major, minor or unknown were the same for both verification 
data sources.  
 
The findings of the study presented in Chapter 6 are reassuring in terms of the 
reliability of malformation recording in the GPRD and they are in line with the 
study by Wurst et al. that verified congenital heart defects.(7) In future studies, to 
minimise the likelihood of misclassification of outcomes, it is still advisable to 
request additional data to verify the cases identified, particularly for 
malformation types where the severity of the condition is required to determine 
whether to categorise as major or minor. Although this study found photocopied 
medical records more informative for verification than free text comments this 
may change. In recent years, GPs have started to record more information in the 
free text fields and it is therefore plausible that the extent of information 
available and the value of free text comments may be greater in the future. 
Furthermore, the method used in this study to identify the free text for review 
could be refined to make it more cost and time efficient. This would involve 
requesting only text recorded in association with a medical code of interest or 
during a particular time period, rather than requesting all free text recorded 
within an individual’s entire medical record. All work to verify MCMs will not only 
improve the robustness of the study but will also add to the body of evidence on 
the accuracy or otherwise of recording in the GPRD. 
 
It is accepted that not all major congenital malformations will be identified via 
the electronic medical records, however no attempts have been made to 
quantify this by evaluating the specificity of congenital malformation recording. 
This is likely to reflect the large amount of time and cost involved in such a task. 
In 2007, Wurst et al. reported on the rates of congenital heart defects in the 
GPRD compared with those of UK registries reporting to EUROCAT and the 
National Congenital Anomaly System.(8) They found the rates to be higher in the 
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GPRD than both the other sources, which is promising in terms of the specificity 
of recording although to my knowledge the completeness of reporting to these 
two systems is unknown. The selection of a suitable comparator with which to 
evaluate the completeness of recording is difficult, yet more studies evaluating a 
range of malformations in this way could provide a valuable contribution to the 
field.  
 
In addition to major congenital malformations, infants can also be born with 
minor malformations that have little structural significance. Minor 
malformations are often only reported to pregnancy registries when they are 
accompanied by a major malformation or there are multiple minor 
malformations present that could be indicative of a syndrome. The recording of 
minor malformations was not evaluated in this study using the GPRD, however 
given their minor clinical significance it is plausible that recording will be less 
complete and more sporadic than for major malformations. 
 
Comparison with the UK Epilepsy and Pregnancy Register 
 The sixth objective aimed to bring together all the aspects of the GPRD that 
had been evaluated as part of the first five objectives. This involved carrying 
out a risk assessment study using GPRD data to compare the prevalence of 
pregnancy outcomes with a major congenital malformation, following a 
range of first trimester anticonvulsant exposures, with those reported by the 
UK Epilepsy and Pregnancy Register. 
 
All the relevant information required to carry out a risk assessment study was 
available from the GPRD. To enable a comparison to be made with the UK 
Epilepsy and Pregnancy Register, prenatally diagnosed malformations that 
resulted in a termination of pregnancy were identified in addition to those in live 
born infants identified in objective four. At the time of this study there was no 
automated way to identify induced terminations that followed a prenatal 
diagnosis so free text comments associated with all pregnancy losses were 
requested and reviewed. This method was found to be effective and identified 
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14 additional major congenital malformations. It was, however, costly and time 
consuming and therefore considered an area where more work was required to 
increase the efficiency with which these malformations could be identified.  
 
It was possible to calculate the risk of a pregnancy outcome with a major 
congenital malformation following a range of first trimester anticonvulsant 
exposures, using data from the GPRD. When comparisons were made with the 
UK Register, what became apparent was that even though the size of the 
database is large, the number of pregnancies to women exposed to any 
particular product was small and much lower than that captured by the 
pregnancy register. These small sample sizes subsequently led to wide 
confidence intervals and, hence, considerable uncertainty regarding the risk 
estimates.  
 
The size of the UK population captured by the GPRD is continuously growing and 
at present is almost twice as large as it was when this study was carried out. 
Despite this however, for the time being at least, the GPRD will be more suited to 
evaluating the risks associated with medicines used to treat more prevalent 
conditions or products that result in a substantial increase in risk. In addition, 
there are also many prescription products that have been on the market for 
some time whose safety during pregnancy has never been evaluated. It is 
possible that these products, even if the teratogenic risk is low, could have the 
potential for a considerable public health impact if they were commonly used by 
pregnant women.(9) The readily available nature of GPRD data may enable the 
safety of these products to be investigated without the time and expense that 
would be encountered by using other data sources. 
 
Some differences were observed between the GPRD and the UK Register and 
these may in part be explained by the differences in data collection methods. 
The proportional representation of patients exposed to the different 
anticonvulsants in monotherapy differed between the two data sources. It is 
possible that this could be the result of selection bias in reporting to the Register 
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with patients or healthcare professionals being more likely to enrol women 
exposed to newer products for which less is known about their safety.  
 
The similarity in the risk estimates for monotherapy versus polytherapy exposure 
for the two data sources was reassuring. Differences were, however, observed in 
risk estimates for the most commonly reported monotherapy exposures. The 
fact that lower rates were observed in the GPRD following valproate exposure 
yet higher rates were observed following carbamazepine exposure makes it 
difficult to determine the reason behind the discrepancies as given the lower 
than baseline risk identified with carbamazepine in the Register, it does not 
appear to be as simple as under- or incorrect reporting in the GPRD.  
 
The UK Register study findings also highlight the issue of the appropriateness of 
comparator groups. As mentioned in Chapter 2, selecting appropriate 
comparator groups when evaluating data from pregnancy exposure registries is 
difficult. For conditions where discontinuing drug therapy is not an option, it may 
be more informative to make comparisons with other treatment groups as was 
done by the UK Register. This is valid as long as women with more serious 
epilepsy who require more continuous monitoring by epilepsy specialists are not 
more likely to enrol than those whose epilepsy is well controlled. An advantage 
of the GPRD is the ability to have multiple comparator groups that have been 
recruited in the same way without adding much additional time and cost to a 
study. In addition, the representativeness of the population captured by the 
GPRD is a great strength and in many cases will ensure a greater generalisability 
of study findings to the wider population. 
 
In addition to unadjusted risk estimates, the UK Register also reported risk 
estimates adjusted for age at delivery, parity, family history of a congenital 
malformation, periconceptional folic acid and the sex of the infant. The work 
presented in Chapter 7 did not attempt to calculate adjusted risk estimates for 
the GPRD data. Data sources that involve a maternal interview have the benefit 
of being able to obtain accurate information on factors such as parity, a family 
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history of congenital malformations and folic acid exposure, which in some cases 
may have been purchased over the counter.  
 
Within the GPRD data is available on some potential risk factors. These include 
alcohol intake, smoking status, body mass index, socioeconomic status, co-
prescribing and co-morbidities. To my knowledge, only one study has evaluated 
alcohol and smoking recording in the GPRD.(10) The percentage of individuals who 
could be identified as a smoker in the GPRD was lower than that reported by the 
UK Office for National Statistics, whilst the percentage classified as an alcohol 
drinker was similar for the two sources. More work, however, is required in 
verifying the accuracy of the recording of this information and the algorithms 
used to categorise individuals.  
 
Identification of a known teratogenic association in the GPRD 
 The seventh objective was to determine whether using GPRD data it was 
possible to identify the known teratogenic association between monotherapy 
first trimester exposure to valproate and an increased risk of a pregnancy 
outcome with spina bifida.  
 
Pregnancies within a cohort of women with a diagnosis of epilepsy where the 
woman had been exposed to valproate as monotherapy during the first trimester 
were successfully identified in the GPRD. Seven cases of spina bifida were 
identified; one resulted in a live birth and six in a termination of pregnancy. Four 
of the cases were among the 225 first trimester monotherapy valproate-exposed 
pregnancies, two were among the 902 pregnancies unexposed to an AED and 
one was exposed to AEDs in polytherapy. An eight-fold increase in spina bifida 
risk was identified in those pregnancies exposed to valproate in monotherapy 
compared to those with no AED exposure (RR 8.02; CI95 1.5-43.5). 
 
The valproate and spina bifida section of the study presented in Chapter 7 
demonstrates that it is possible to identify a known teratogenic association using 
data recorded in the GPRD. This is of particular relevance because the 
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identification of the same teratogenic association formed part of the assessment 
of EUROCAT data to determine its suitability for use to evaluate increases in the 
risk of specific malformations following exposure to anticonvulsants.(11)  The fact 
the majority of spina bifida cases were identified in pregnancies that ended in a 
termination highlights how essential it is that induced terminations of pregnancy 
are captured when serious congenital malformations, detectable at prenatal 
testing, are an outcome of interest. Without the inclusion of induced 
terminations of pregnancy it would not have been possible to replicate the 
association.  
 
Identification and categorisation of pregnancy losses in the GPRD 
 Having determined that it was possible to identify, by review of the free text, 
pregnancies that had been terminated following a prenatal diagnosis, the 
final objective was to determine whether this could be done in an automated 
manner. This involved the development of an algorithm to identify pregnancy 
losses in the GPRD to categorise them into those that were spontaneous, 
induced for a foetal medical condition and induced for other reasons.  
 
Pregnancy losses were successfully identified in the GPRD and an algorithm was 
developed to categorise the type of pregnancy loss. Free text comments were 
requested and reviewed for a random sample of 200 pregnancy losses to 
evaluate the reliability of the algorithm. 
 
For 82.0% of pregnancy losses identified in the GPRD there was sufficient 
information in the patient’s medical record for the algorithm to categorise them 
as being spontaneous or induced. For induced terminations of pregnancy, in 
almost two-thirds of cases, it was possible to infer the reason for the termination 
based on the evaluation of medical codes in the patient’s electronic record. 
Review of the additional free text comments for a sample of 200 pregnancy 
losses found agreement between the algorithm end point and the type of 
pregnancy loss for 156 cases, no additional information was available in 36 cases 
and the free text contradicted the algorithm for 8 out of 200 pregnancy losses. 
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The algorithm identified 1.8% of induced terminations as being carried out for 
medical reasons, 0.1% based on the level of detail in the termination code and 
1.7% based on evidence of a planned pregnancy or a code for a congenital 
malformation. 
 
The work presented in Chapter 8 demonstrates that it is possible to identify the 
full range of pregnancy losses in the GPRD. It is considered reassuring that the 
percentage of pregnancies identified as ending in a pregnancy loss is in line with 
what has been reported in the literature and this was also true for the different 
types of pregnancy loss. Using data recorded in the electronic records alone, 
however, there was insufficient information for the algorithm to determine the 
type of loss in around 18.0% of pregnancies and in 37.1% of induced 
terminations the reason was unknown. It is therefore possible that some of 
these could have been terminated following a prenatal malformation diagnosis 
but given the small percentage of all pregnancy losses that fall into this category, 
the total number and subsequent impact of this is likely to be small. The 
percentage of induced terminations carried out following a prenatal diagnosis of 
a congenital malformation may have been slightly overestimated using the 
algorithm, however the extent to which this occurs appears to be low. For these 
potential prenatally diagnosed cases, review of the associated free text 
comments is recommended to confirm malformation status. This will help avoid 
incorrect risk estimates that could lead to unnecessary concern or a false sense 
of security for women taking the product of interest. 
 
The ability to capture pregnancy losses is a significant strength of the GPRD and 
is one aspect that could enable it to complement other more commonly used 
data sources in the area of drug safety in pregnancy. In addition to pregnancy 
losses the GPRD also has the potential to provide data on other adverse 
pregnancy outcomes; these include premature deliveries, stillbirths, pre-
eclampsia and neonatal deaths. To my knowledge the recording of these 
pregnancy outcomes in the GPRD has not been evaluated but it is something that 
is going to be carried out as part of a drug safety in pregnancy study currently 
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being under taken within the Pharmacoepidemiology unit at the University of 
Bath.  
 
9.2 Current developments  
Drug utilisation studies are important in drug safety in pregnancy research for 
determining priorities of study(9) and for understanding the patient 
characteristics of user group populations to help interpret potential signals 
generated from sources such as registries. The presence of pregnant women 
regardless of exposure, in automated healthcare databases and some linked 
population-based surveillance systems, means there is a known denominator 
and this enables the prevalence of exposure to particular products to be 
calculated. This therefore makes these data sources particularly suitable for drug 
utilisation studies.  
 
The European Commission is currently funding an Seventh Framework 
Programme focussing on the safety of medicine use in pregnancy.(12) This study 
aims to evaluate the safety of products in four therapeutic drug classes 
(anticonvulsants, SSRIs, anti-asthma medicines and diabetes medicines) whilst 
also obtaining information on drug utilisation patterns. The drug utilisation 
aspect of the study will collate data from the GPRD in addition to databases in 
the Netherlands, Italy, Denmark, Norway and Wales. Some of the databases have 
already established themselves within the field of drug safety research(4, 13-15) but 
others like the SAIL database in Wales are being utilised in this way for the first 
time.  
 
This thesis has demonstrated there are many factors that need to be taken into 
account when using the GPRD for drug safety in pregnancy research. As the 
number of researchers using automated healthcare databases increases, it is 
important to continue sharing what is known about the intricacies of using these 
data sources and the importance of fully understanding the healthcare system 
from which the data has been collected. This knowledge can be shared via 
publications and commentaries in peer reviewed journals and through 
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workshops, symposia and meetings that are organised by the Drug safety in 
Pregnancy Special Interest Group that meet once a year at the International 
Conference of Pharmacoepidemiology.  
 
One development that may go some way to ensuring high standards and 
improving the scientific rigor of studies is the creation of the European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). This 
aims to “improve pharmacoepidemiological research and post-authorisation 
safety surveillance of medicinal products in Europe by offering access to a robust 
network of resources working in a transparent and independent manner 
according to the highest scientific standards”.(16) The ENCePP working groups 
have drawn up a detailed study protocol check list which it hopes will encourage 
researchers to consider all important aspects of study design. In addition to 
which, to increase transparency, all studies eligible for ENCePP approval need to 
have their study protocol posted to the ENCePP website before the study 
commences. Finally the latest developments at ENCePP include the creation of 
Special Interest Groups with the aim to facilitate discussions between the EMA 
and its Committees and ENCePP. It is possible one such special interest group 
might focus on drug safety in pregnancy. 
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9.3 Overall conclusions 
The work carried out as part of this thesis, which aimed to evaluate the utility of 
the General Practice Research Database to act as an alternative or complement 
to pregnancy registries, has demonstrated that: 
 
1. It is possible to identify all types of pregnancy outcome, including pregnancy 
losses, in the GPRD.  
 
2. First trimester exposure to anticonvulsants can be determined by identifying 
and mapping prescription records. 
 
3. Within the GPRD it is possible to link the mother’s medical record to that of 
the child in over 90% of live deliveries. 
 
4. A range of major congenital malformations can be identified from codes in 
the child’s and mother’s GPRD medical records. 
 
5. The reliability of major congenital malformation recording is high but 
verification of those identified as part of future studies is recommended. 
 
6. Using an algorithm it is possible to categorise 80% of pregnancy losses in the 
GPRD. Review of the free text comments is still required, however, to confirm 
terminations of pregnancy that followed a prenatal malformation diagnosis.  
 
7. It is possible to carry out a risk assessment study using data from the GPRD 
and to identify a known teratogenic association. 
 
 
The GPRD was found to have a number of key strengths for drug safety in 
pregnancy research when compared with some other data sources. These 
include the representative nature of the population captured, the availability of 
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the data, the ability to identify all types of pregnancy outcome, the potential for 
large sample sizes and the presence of a denominator population.  
 
The capability of the GPRD is likely to be restricted, however, by small sample 
sizes when evaluating products used to treat less prevalent conditions, the 
inaccuracies associated with establishing exposure based on the issue of a 
prescription and a lack of information on some potential confounding factors 
such as over-the-counter folic acid exposure. Further validation of the algorithms 
used to identify pregnancies and categorise pregnancy losses are required in 
addition to verifying the recording of other adverse pregnancy outcomes. 
 
At present the GPRD is most suited to use for carrying out studies of drug 
utilisation in pregnant women and evaluating the safety of medicines used to 
treat chronic and more prevalent conditions or those where there is a substantial 
increase in risk. It has been frequently commented that it is unlikely a single data 
source or study design will be sufficient for monitoring all aspects of the safety of 
medicine use during pregnancy.(17, 18) This thesis has demonstrated that the 
General Practice Research Database has the potential to make a valuable 
contribution to the field of drug safety in pregnancy and could play an important 
role in complementing the work of other surveillance systems including 
pregnancy exposure registries and case-control systems.  
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